Phase I Study of Intraperitoneal Cantrixil in Patients with Persistent or Recurrent 
Ovarian Cancer, Fallopi[INVESTIGATOR_826730]
[STUDY_ID_REMOVED]
Study Protocol
Date 30 April 2018
Clinical Study Protocol   
 
 
 
 
 
 
 Phase I Study of Intra -peritoneal Cantrixil in Patients with 
Persistent  or Recurrent Ovarian Cancer, Fallopi[INVESTIGATOR_826731] . 
 
Protocol Number:  NVGN -002-101 
IND Number:  [ADDRESS_1146957]:  Cantrixil (TRX -E-002-1 in 20% Dexolve -7) 
 
Indication:  Ovarian, Fallopi[INVESTIGATOR_59122], or Peritoneal Cancer  
 
Clinical Phase:  Phase I  
Principal 
Investigator s: 
 Principal Investigator  
[INVESTIGATOR_826732] (Lead PI [INVESTIGATOR_826733])  
A/[CONTACT_826824] (Lead PI [INVESTIGATOR_826734])  
 
Sponsor:  
 Kazia Therapeutics  Limited  
Three International Towers  
Level 24, [ADDRESS_1146958]  
Sydney NSW 2000, Australia  
Australia  
Version:  
 4.0 
Date:  
 30 April  2018 
This protocol is the confidential property of Kazia Therapeutics Limited , and is 
intended solely for the guidance of this clinical investigation. This protocol may 
not be disclosed to parties not associated with the clinical investigation or used 
for any other purpose without the prior written consent of Kazia Therapeutics 
Limited. 
CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version:  4.0  
Date:  30 April 2018  Clinical Study Protocol  
Protocol Number:  NVGN -002-101 
IND Number:  123275  
 
 
Page 2 of 92 DOCUMENT HISTORY  
 
Version  Date  Reason for amendment  Summary of changes  Substantial 
amendment 
(Y/N)  
2.0 07 
September 
2016  Incorporate changes as 
per FDA recommendations  Define allowed 
combination 
chemotherapi[INVESTIGATOR_826735].  
Update eligibility criteria 
as per FDA advice.  
Include assessment by 
[CONTACT_6802]/B of Cantrixil 
monotherapy PK data 
before beginning 
combination therapy for 
each patient.  
Amend errors or 
ambiguities in languag e 
for improved clarity.  Y 
CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version:  4.0  
Date:  30 April 2018  Clinical Study Protocol  
Protocol Number:  NVGN -002-101 
IND Number:  [ADDRESS_1146959] 8 cycles; Remove 
Part C; Incorporate 
Changes as per HREC 
recommendations  Add an additional 
extended access cohort 
to the study.  
Remove all references to 
Part C.  
Update names and 
contact [CONTACT_826770].  
Update language to 
improve clarity of protocol  
and correct errors that 
had been identified . 
 Y 
4.0 30 April 
2018  Update Novogen name 
[CONTACT_826821] o n 15th November 
2017 ;  
Update Corporate Address  
post move 5th February 
2018;  
 
 
 
 
Remove Biomarker sample 
from part B  
 
 
Update Quintiles name 
[CONTACT_826822] [ADDRESS_1146960]  
Sydney NSW 2000, 
Australia ; 
Remove all references to 
the collection of the 
Biomarker sample in Part 
B. 
 
Changed all references of 
Quintiles to IQVIA  Y 
 
 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics L imited  
Version:  4.0 
Date:  30 April 2018  Clinical Study Protocol  
Protocol Number:  NVGN -002-101 
IND Number:  [ADDRESS_1146961] OF ABBREVIATIONS  ................................ ................................ ......... 19 
4 INTRODUCTION  ................................ ................................ .......................... 21 
4.1 Background Information  ................................ ................................ ................. 21 
4.1.1  Pre-Clinical Findings  ................................ ................................ .................  22 
4.2 Rationale  ................................ ................................ ................................ ......... 24 
4.3 Risk Assessment  ................................ ................................ ............................. 25 
4.4 Urgent safety measures  ................................ ................................ ................... 25 
5 STUDY OBJECTIVES ................................ ................................ ................... 26 
5.1 Primar y Objectives  ................................ ................................ ......................... 26 
5.2 Secondary Objectives  ................................ ................................ ..................... 26 
5.3 Exploratory Objectives  ................................ ................................ ................... 26 
6 INVESTIGATIONAL PLAN  ................................ ................................ ......... 27 
6.1 Overall Study Design  ................................ ................................ ...................... 27 
6.1.1  Data Safety Monitoring Committee/Board  ................................ ................  [ADDRESS_1146962] Exclusion Criteria  ................................ ................................ .........  40 
6.2.3  Restrictions  ................................ ................................ ................................  41 
[IP_ADDRESS]  Avoidance of Pregnancy  ................................ ................................ ................. 42 
[IP_ADDRESS]  Acceptable Forms of Contraception  ................................ ............................... 42 
[IP_ADDRESS]  Time Period for the Collection of Pregnancy Information  ............................. 43 
[IP_ADDRESS]  Follow -up in the Event of a Pregnancy  ................................ .......................... [ADDRESS_1146963](s)  ................................ ................................ ............... 45 
7.1.1  Supply, Packaging and Labelling  ................................ ..............................  45 
7.1.2  Storage and Handling Procedures  ................................ ..............................  45 
7.1.3  Accountability  ................................ ................................ ............................  45 
7.2 Dosage and Administration  ................................ ................................ ............ 46 
7.3 Treatment Strategy  ................................ ................................ .......................... 47 
7.4 Warnings and Precautions  ................................ ................................ .............. 48 
7.5 Prior and Concomitant Medication  ................................ ................................ .48 
7.6 Method of Assigning Subjects to Treatment Groups ................................ ......48 
7.7 Randomisation Procedures (Not applicable)  ................................ .................. 49 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 5 of 92 7.8 Maintenance of Randomisation Codes (Not applicable)  ................................ 49 
7.9 Blinding (Not applicable)  ................................ ................................ ............... 49 
8 STUDY PROCEDURES  ................................ ................................ ................ 50 
8.1 Pharma cokinetic Assessments  ................................ ................................ ........ 50 
8.2 Efficacy Assessments  ................................ ................................ ..................... 50 
8.3 Safety Assessments  ................................ ................................ ......................... 52 
8.3.1  Adverse Events  ................................ ................................ ..........................  52 
8.3.2  Reporting of Adverse Events  ................................ ................................ ..... 53 
8.3.3  Categorisation of Adverse Events ................................ ..............................  53 
8.3.4  Causal Relationship Assessment  ................................ ...............................  54 
8.3.5  Action Taken ................................ ................................ ..............................  54 
8.3.6  Outc ome ................................ ................................ ................................ ..... 54 
8.3.7  Coding of Adverse Events  ................................ ................................ .........  55 
8.3.8  Pregnancy Reporting ................................ ................................ ..................  55 
8.4 Clinical Laboratory Safety Tests  ................................ ................................ ....55 
8.5 Clinical Safety Assessments  ................................ ................................ ........... 56 
8.5.1  Physical Examination  ................................ ................................ ................  56 
8.5.2  Vital Signs ................................ ................................ ................................ .. 56 
8.5.3  12-Lead Electrocardiogram (ECG)  ................................ ............................  56 
8.5.4  Medical History  ................................ ................................ .........................  56 
8.6 Follow -up Assessments  ................................ ................................ .................. 57 
9 DATA COLLECTION  ................................ ................................ ................... 58 
10 EVALUATION OF STUDY DATA  ................................ .............................. 60 
10.1  Evaluation of Pharmacokinetic Parameters  ................................ .................... 60 
10.2  Evaluation of Pharmacodynamic/Efficacy Measures  ................................ .....[ADDRESS_1146964] Populations for Analyses  ................................ ................................ ...62 
11.3  Pharmacokinetic Analysis ................................ ................................ ............... 62 
11.4  Efficacy Analysis  ................................ ................................ ............................ 63 
11.5  Exploratory Analysis  ................................ ................................ ...................... 63 
11.6  Safety Data Analysis  ................................ ................................ ....................... 63 
12 STUDY REPORT  ................................ ................................ ........................... 66 
13 REGULATORY AND ETHICAL ISSUES  ................................ ................... 67 
13.1  Regulatory and Ethics Review and Approval  ................................ ................. 67 
13.2  Informed Consent  ................................ ................................ ........................... 67 
13.3  Indemnity and Compensation  ................................ ................................ ......... 68 
14 STUDY MANAGEMENT  ................................ ................................ ............. 69 
14.1  Quality Assurance and Quality Control  ................................ .......................... 69 
14.2  Protocol Adherence ................................ ................................ ......................... 69 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: [ADDRESS_1146965] Retention  ................................ ................................ .................. 71 
14.7  Publication Policy  ................................ ................................ ........................... 71 
15 REFERENCES  ................................ ................................ ............................... 72 
16 STUDY SCHED ULE  ................................ ................................ ..................... 75 
17 PROTOCOL SIGNATURES  ................................ ................................ ......... 80 
 
 
 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: [ADDRESS_1146966] OF TABLES  
Table 1  Permitted Combination Therapi[INVESTIGATOR_014]  ................................ ................................ ... 27 
Table 2  Doses at each Dose Level  ................................ ................................ ................  28 
Table 3  3+3 Design Dose -escalation Plan  ................................ ................................ .... 36 
Table 4  Schedule of Assessments  ................................ ................................ .................  76 
Table 5  Proposed PK Schedule (Part A and Part B)  ................................ .....................  [ADDRESS_1146967] OF FIGURES  
Figure 1  Proposed Dosing Schema  ................................ ................................ ................  34 
 
 
 
APPENDICES  
Appendix A: Study Contacts ................................ ................................ .............................. 82 
Appendix B: Procedures for the placement of the Intraperitoneal port/ catheter and 
administration of Intraperitoneal therapy  ................................ ................................ ........... 84 
Appendix C: Evaluation of response and progression using gynecological cancer 
intergroup (GCIG) response criteria  ................................ ................................ .................. 89 
 
 
 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 8 of 92 2 TABULATED PROTOCOL SUMMARY  
 
Name [CONTACT_790]/Company:  Kazia Therapeutics Limited  
Name [CONTACT_2756](s):  Cantrixil  
Name [CONTACT_3261](s):  TRX -E-002-1 (in 20% Dexolve -7) 
Title of Study:   
Phase I Study of Intra -peritoneal Cantrixil in Patients with Persistent  or Recurrent Ovarian Cancer, 
Fallopi[INVESTIGATOR_826736] s: 
 [INVESTIGATOR_826732]  (National PI) , Lifespan Cancer Institute, Rhode Island Hospi[INVESTIGATOR_307], Providence, RI, [LOCATION_003]  
A/[CONTACT_826825], Oklahoma Health Sciences Ce nter, Oklahoma City, OK, [LOCATION_003]  
[CONTACT_826826], Mary Crowley Cancer Center, Dallas, TX, [LOCATION_003]  
A/[CONTACT_826827] (Jim) Coward  (National PI) , ICON Cancer Care, South Brisbane, QLD, Australia  
[CONTACT_826828] , Flinders Medical Centre, Adelaide, SA, Australia  
[CONTACT_826829], Westmead Adults Hospi[INVESTIGATOR_307], Westmead, NSW, Australia  
Investigational Site:  
The study will be conducted in approximately 5 to 6 study centres  in Australia and the [LOCATION_002] 
(US).  
Clinical Phase:  Phase I 
Objectives:  
Primary Objective  
• To determine the maximum tolerated dose ( MTD ) of Cantrixil when delivered as a single agent , 
administered intraperitoneally , at a weekly administration frequency .  
• To evaluate the safety and tolerability of Cantrixil delivered  via intraperitoneal administration 
as a single agent and in combination with standard chemotherapy  when administered weekly . 
• To characterise the pharmacokinetics ( PK) of intraperitoneal  Cantrixil when delivered as a 
single agent and in combination with st andard chemotherapy.  
Secondary Objectives  
• To evaluate progression free survival  (PFS). 
• To evaluate the time to paracentesis and the volume of malignant ascites drained at each 
paracentesis event (for those patients with malignant ascites).  
• To evaluate the potential anti -cancer  activity of Cantrixil using Response Evaluation Criteria in 
Solid Tumours (RECIST) criteria, version 1.1 and CA -125 measurements . 
• To evaluate the change in cancer antigen 125 (CA -125) in peripheral blood before and after 
treatment wit h Cantrixil.  
Exploratory Objectives  
• To evaluate the safety, tolerability and activity of Cantrixil when administered intraperitoneally 
as a single agent and in combination at a twice -weekly administration frequency.  
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 9 of 92 • To evaluate the change in the number of circulating epi[INVESTIGATOR_826737] (C ETCs) in 
peripheral blood and malignant ascites (if present) before and after treatment  with Cantrixil . 
• To evaluate the clonogenicity of C ETCs in peripheral blood and malignant a scites (if present) 
before and after treatment  with Cantrixil . 
• To evaluate the expression of stem cell markers, CD44 and ALDH in colonies  isolated in the 
clonogenicity assays.  
Methodology:  
This study is a progressive design with 2 discrete Parts (Part A: Dose escalation, Part B: Dose 
expansion). Cycle 1/Part A is a dose -finding assessment (dose escalation) to establish the MTD of 
Cantrixil when administered as a single dose once a week  for 3  weeks. Cycle  2/Part A continues with 3 
additional weekly  doses of Cantrixil as a monotherapy before an assessment of disease response.  In 
Cycles  3 to 8/Part A , patients will be administered the same once -weekly dose of Cantrixil they tolerated 
in Cycle s 1 and 2  (tolerance defined as no dose limiting toxicities [DLTs]  or unacceptable adverse events 
[AEs] ) in combination with standard chemotherapy agent(s), in order to assess the safety and tolerability 
of Cantrixil in combination therapy. Standard chemotherapy drugs will be administered at the standard 
efficaciou s dose  and dosing schedule  to maintain optimum benefit of known therapeutic agents  for 
patients . Treating physicians may choose the combination therapy from the list in Table [ADDRESS_1146968] 
be diligently recorded in the patients’ electronic case report form (eCRF).  
Once the MTD has been determined in Part  A/Cycle [ADDRESS_1146969] not be shorter than 7 days. For 
other intraperitoneal access devices, the period may be shorter if adequate stability and/or healing of the 
delivery system’s insertion site is co nfirmed by [CONTACT_1963] . 
Patients should begin protocol treatment within a maximum of 28  days of enrolment (i.e., signing of 
consent form).  
Patients will start at Dose Level 0 (see  Table 2) which is calculated to be the human equivalent of 10% 
of the STD10 dose in rats (dose is 1/10 the severely toxic dose in 10% of rats tested). Dose levels -1 
and -2 will only be activated if there are 2  DLT s at the Dose Level 0  and -1, respectively . Single patient 
cohorts will be treated with increasing doses of Cantrixil until an AE is observed during Part A/Cycle 1 
that meets the definition of a DLT or , in the opi[INVESTIGATOR_826738] /Board 
(DSMC/B) and the Investigator, warrants observing additional patients at this dose level; at this point the 
study will revert to a 3+3 rules -based dose escalation study. The decision to expand from single patient 
cohorts to 3 patient cohorts is crit ical for the safety of participants and will be made with input from the 
Investigator and DSMC/B responsible for this study.  Once the study enters a 3+3 rules -based design, the 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: [ADDRESS_1146970] chemotherapy at their discretion and if it is considered safe 
and in the patient’s best interest.  
If any of the following unacceptable AEs or DLTs are observed and unless clearly unrelated to study 
treatment (e .g., disease progression), treatment at the currently allocated Cantrixil dose will be paused. 
At this point a dose reduction may be considered or the treatment may be terminated, depending on what  
is considered by [CONTACT_826771]’s best interest .: 
• Hematologic toxicity  
o Grade [ADDRESS_1146971] 5 days , 
o Grade 3 or Grade 4 neutropenia associated with fever >38.5°C ,  
o Grade [ADDRESS_1146972] 5 days ,  
o Grade 3 thrombocytopenia associated with severe bleeding in the opi[INVESTIGATOR_684] , 
o Dose delay of ≥3 weeks due to failure to recover counts . 
• Any Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 Grade 3 or 
Grade 4 non -haematol ogical toxicity except:  
o Alopecia  
o Grade 3 abdominal pain deemed related to the port or catheter as determined by [CONTACT_47806]  
o Grade 3 anorexia  
o Grade 3 fatigue  
o Grade 3 nausea and/or vomiting, or diarrhoea , lasting ≤48 hours with o r without 
maximal medical management.  
o Grade 3 dehydration as a result of nausea and vomiting  
o Grade 3 constipation  
o Grade 3 metabolic abnormalities [ hypokalaemia , hypomagnesemia, hypocalcaemia , 
hypophosphatemia]) that recovers to Grade 1 or less within 48 hou rs with or without 
medical management  
• Other serious adverse events (SAEs) which, in the opi[INVESTIGATOR_12980] , 
necessitate temporary or permanent cessation of administration  
• Treatment delays of ≥3 weeks due to any non -haematological toxicity  will constitute a DLT  
All patients who discontinue  (i.e. are now Off Therapy/ End of Therapy) from the study treatment will 
progress to follow -up unless the patient withdraws consent.  
The initiation of each new cycle of Cantrixil will be at the discretion of the Investigator and will depend 
on the potential or measurable benefit to the patient assuming continued tolerability  and adequate organ 
function . 
Cantrixil treatment will be stopped due to RECIST version 1.[ADDRESS_1146973] 2 cycles of combination therapy , recurrence of unacceptable toxicity after 1 Cantrixil dose 
reduction or patient consent withdrawal. Note that  patients with progressive disease at the end of 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: [ADDRESS_1146974] version 1.1 criteria but who, in the opi[INVESTIGATOR_684], continued to derive clinical benefit may continu e Cantrixil treatment. Patients may also be 
discontinued from study treatment if the Investigator considers continuing therapy is not in the patient’s 
best interest. All patients discontinued from study treatment (i.e. are now Off Therapy/ End of Therapy) 
will progress to follow -up unless the patient withdraws consent.  
Tumour assessment via radiological imaging will be conducted during screening and every [ADDRESS_1146975] -
enhanced magnetic resonance imaging (MRI) or contrast -enhanced computed tomography (CT) may be 
used, but once a modality is used at baselin e this must be used consistently for that patient throughout 
their participation on the study. Other imaging is not mandatory, but may be performed if clinically 
indicated.  
Adverse events will be monitored for the duration of the study from the time of in formed consent. Blood 
samples will be collected weekly for standard safety testing, or more frequently if clinically relevant, 
during the study. Additional volumes of blood will be collected before and after administration of 
Cantrixil for PK analysis (4 m L per time point as per the proposed PK schedule [Table 5]) and for any 
exploratory studies (at baseline, end of Cycle 2 and End of Therapy , 15 to 20 mL at each time -point).  
Part A (Dose escalation of Cantrixil as a monotherapy ):  
Cycle 1  
Following placement of a port or catheter, eligible patients will be admi nistered a single dose of the 
study treatment Cantrixil (TRX -E-002-1 formulated  in Dexolve -7) intraperitoneal ly once a week for 
3 weeks. Patients will be monitored for DLTs over the 21 -day cycle (Cycle 1).  
Blood samples will be collected weekly at each sc heduled visit for standard safety testing, or more 
frequently if clinically relevant. Results of the safety assessments must be available prior to Cantrixil 
administration to ensure that all assessments still meet inclusion  criteria as described in Section  6.2.1  and 
it is safe to proceed to the next dose of treatment. Treatment delays of up to three weeks are allowed for 
recovery without being classified as a protoco l deviation or a dose limiting toxicity.  
Patients will continue to be monitored until they meet the study discontinuation criteria but will only be 
evaluable for DLTs that define the MTD of Cantrixil as a monotherapy during Cycle  1/Part A.  
Patients will s tart at Dose Level 0 (see  Table 2) which is calculated to be the human equivalent of 10% 
of the STD10 dose in rats (dose is 1/10 the severely toxic dose in 10% of rats tested). Dose levels -1 and 
-2 will only be activated if there are 2 DLT s at the Dose Level 0  and -1, respectively . Singl e patient 
cohorts will be treated with increasing doses of Cantrixil until an AE is observed during Part A/Cycle 1 
that meets the definition of a DLT or  in the opi[INVESTIGATOR_557182]/B and the Investigator, warrants 
observing additional patients at this dose level; at this point the study will revert to a 3+3 rules -based 
dose escalation study (see Section  6.1.2 ). The decision to expand from single patien t cohorts to 3 patient 
cohorts is critical for the safety of participants and will be made with input from the Investigator and 
DSMC/B responsible for this study (see Section 6.1.1 ). 
Cycle 2  
Patients that are still on study treatment at the end of Cycle 1/Part A will receive another cycle of 
Cantrixil monotherapy with once weekly dosing before disease assessment. Note that a disease 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: [ADDRESS_1146976] not discontinued from the study at the end of Cycle 2 will proceed to Cycles  3 to 
8/Part A of the study.  
Cycles 3 to 8 (Cantrixil in Combination with Standard Chemotherapy)  
Patients that progress to Cycles 3 to 8/Part A will continue on the same dose level of Cantrixil that they 
tolerated in Cycle s 1 and 2 /Part A, but in combination with systemic chemotherapy selected from Table 
1 by [CONTACT_1963]/Investigator.   
During Cycles 3 to 8 /Part A, patients will be admi nistered Cantrixil once per week for each 21 -day 
cycle. In addition to Cantrixil, patients will receive the chemotherapy selected  by [CONTACT_826772] 1. Before administration of the combination chemotherapy, the PK 
results for each patient from Part A/ Cycle [ADDRESS_1146977] be diligently recorded in the patient’s eCRF . 
Part B (Expansion Cohort at MTD):  
Once the MTD has been established, an expansion cohort will be recruited at the MTD. An additional 
12 patients will be recruited in this cohort on top of those recruited in Part  A at the MTD. These patients 
will be subjected to the same intervention described above with 2 cycle s of monotherapy followed by [CONTACT_25765] 6 cycles of combination therapy.  
Continued Ac cess for Patients:  
Patients who complete the planned [ADDRESS_1146978] agree to on -going data collection for monitoring safety, progression and 
survival.  
Number of S ubjects:  
Six to 54 (includes up to 42 in Part A  and12 in Part B) patients with persistent  or recurre nt ovarian 
cancer, fallopi[INVESTIGATOR_472244].  
Main C riteria for Inclusion:  
Patients with the following disease criteria are eligible for this study:  
1. Patients must have recurrent or persistent epi[INVESTIGATOR_12253], fallopi[INVESTIGATOR_8916], or primary 
peritoneal cancer. The original diagnosis  must be verified by a histology report. All histological 
sub-types and all grades of disease are eligible to participate; gr ade, histological sub -type and 
breast cancer susceptibility gene (BRCA) status must be recorded at study entry.  
2. Patients must be female and at least [ADDRESS_1146979] -feeding and able to adopt adequate 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 13 of 92 contraception as described in section [IP_ADDRESS].  
3. Patients with malignant ascites are eligible to participate; paracentesis will be conducted before 
the administration of Cantrixil. Drainage of the maximum volume of ascites s hould be 
performed according to local standard operating procedures before administration of Cantrixil.  
4. Patients must have completed at least two (2) or more prior regimens  (including adjuvant 
therapy) for their ovarian, Fallopi[INVESTIGATOR_826739] l cancer prior to participation in 
the current study; all prior therapi[INVESTIGATOR_826740]. Patients that have received 
prior intraperitoneal therapy are eligible for this study. Patients should have failed standard of 
care drugs prior to being  eligible to be part of the proposed study.  
 
5. Patients must have  platinum -resistant relapsed disease, platinum refractory disease, or have 
documented intolerance to platinum therapy . Patients will not be eligible based on rising 
CA-[ADDRESS_1146980] other clinical symptoms (such as malignant 
ascites) or radiological tumour measurements that support disease recurrence or 
progression.  
6. At least [ADDRESS_1146981] passed from any previous therapy and any toxicities from prior 
therapi[INVESTIGATOR_014] (6  weeks for bevacizumab, nitrosoureas or mitomycin  C treatment) must have 
resolved to less than or equal to Common Terminology Criteria for Adverse Events (CTCAE 
version  4.03) Grade [ADDRESS_1146982] a performance status of Eastern Cooperative Oncology Group (ECOG) 
0 to 2 and, in the Investigator ’s opi[INVESTIGATOR_1649] , be able to complete at least a major part of the study . 
8. Patients must be willing and able to under go insertion of a port or catheter for intraperitoneal  
access; the type of port or catheter used will be recorded.  
9. Patients may  have measurable or non -measurable disease; disease  response and progression will 
be measured and assessed according to RECIST  version  1.[ADDRESS_1146983] acceptable hepatic and marrow function as defined below:  
11. Absolute neutrophil count >1.5 x 109/L 
12. Platelets >100 x 109/L 
13. Total bilirubin; <2.5 times the institutional upper  limit of normal (ULN)  
14. Haemoglobin (Hb) of >10 g/dL; patients with Hb >9g/dL will be considered for this study if 
they have not received a transfusion or other bone marrow support. Patients with Hb >10  g/dL 
that have received a recent transfusion will only  be eligible if there has been a wash -out period 
of 7 days for rhesus factor and 10 days for platelet transfusions, respectively . 
15. Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/ alanine 
aminotransferase (ALT) (serum gluta mic pyruvate transaminase [SGPT]) ≤2.[ADDRESS_1146984].  
16. Serum creatinine < 1.[ADDRESS_1146985]  
17. Prothrombin time (PT) or international normalised ratio (INR) ≤1.[ADDRESS_1146986] and activated partial 
thromboplastin time (aPTT) ≤1.[ADDRESS_1146987] be willing and able to comply with all study requirements, including treatment 
timing and/or nature of required assessments and treatment at designated study centre.  
19. Each participant must be adequately informed about the purpose of the study; potential benefits 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 14 of 92 and risks; their right to refuse participation or to withdraw consent at any time; institutional 
affiliation and potential competing interests of the researcher ; and sources of study funding and 
have signed and dated a written informed consent form.  
Main Criteria for Exclusion:  
1. Patients who have had chemotherapy, biologic therapy, immunotherapy, or radiotherapy within 
4 weeks (6 weeks for bevacizumab, nitrosoureas or mitomycin C) prior to entering the study.  
2. Patients must not have had major surgery within [ADDRESS_1146988] receiv ed any other investigational medicinal products (IMPs) or 
participat ed in any oth er interventional clinical research studies  within [ADDRESS_1146989] 
Cantrixil administration . 
4. Patients receiving any medications or substances that are strong inhibitors or inducers of 
cytochrome P450 ( CYP )1A2, CYP2B6 and CYP3A4 or those substances wit h narrow 
therapeutic index are not to be enrolled.  These compounds are prohibited from screening until 
completion of end of therapy  or first post -treatment follow -up visit. For a list of prohibited 
medications see the University of Indiana Clinical Pharmac ology Department’s P450 Drug 
Interaction Table ( http://medicine.iupui.edu/clinpharm/ddis/main -table/ ). Note: the use of 
paclitaxel is allowed, but only 24 hours after Cantrixil administra tion. 
5. Patients deemed by [CONTACT_826773], including but not limited to any one or more of the following;   
• Patients with a recent h istory  (previous 12 months)  of bowel obstruction prior to study 
entry  
• Patients with CT scans that suggest invasion of bowel by [CONTACT_432532]  
• Patients with s ymptoms to suggest impending bowel obstruction   
• Patients with p rior whole abdominal radiotherapy  
• Patients with chronic inflammatory b owel diseases such as Crohn’s disease or 
ulcerative colitis   
6. Patients may not have uncontrolled or severe systemic diseases  or psychiatric conditions , which 
in the treating physician’s opi[INVESTIGATOR_826741]. Screening for chronic conditions is not required.  
7. Patients that are pregnant, lactating, or unable to adopt adequate contraception are excluded. 
Women of childbearing potential must have a negative pregnancy test within [ADDRESS_1146990] tested positive for human immunodeficiency virus (HIV)  
10. Patients with a known hypersensitivity to or serious reaction to benzopyrans are excluded . 
Test Product, Dose and Route  
 of Administration:  
Cantrixil, escalating doses from 0.24  mg/kg to 20 mg/kg, intraperitoneal  administration   
Duration of T reatment:  
The target number of cycles is eight; 21 days per cycle, followed by a maximum of 3 months’ follow -up. 
On-going treatment with Cantrixil, beyond the planned 8 cycles of treatment scheduled in  Parts A and B 
 CONFIDENTIAL  
 
Sponsor:  Kazia Ther apeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 15 of 92 of this study, is an option for patients who, based on the local Investigator’s opi[INVESTIGATOR_1649], are benefiting from 
treatment. All requests  for continued access require discussion with the Sponsor . 
Endpoints  
Primary:  
1. Determination of the MTD of Cantrixil using standard safety monitoring assessments when 
administered as a monotherapy.  
2. Description of the PK of Cantrixil when administered as a monotherapy and in combination 
with standard chemotherapy agent (s). 
Secondary:  
1. PFS will be measured as the time from treatment start until objective disease  progression as 
defined by [CONTACT_44993] 1.1 and/or GCIG criteria.  
2. The time to paracentesis will be measured as the time from treatment initiation  until the next 
paracentesis e vent for ascites .  
3. The volume of abdominal fluid  will be measured by [CONTACT_826774] . 
4. Disease  response will be measured using RECIST version 1.1 criteria ; during Follow -up, 
response may be also assessed using the Gynecological Cancer Intergroup (GCIG) response 
criteria that incorporates CA -125 measurements (see Appendix C).  
5. Concentration of CA -125 in peripheral blood will be assayed in local laboratories using locally 
validated assays at baseline  and then weekly during treatment , at the End of Therapy  and during 
Follow -up. 
Exploratory:  
1. Determination of the optimum dose and administration schedule (i.e. weekly vs twice weekly 
administration) using standard safety monitoring assessments, PK measurem ents and 
tolerability of delivery in the study centre.  
2. Enumeration of C ETC in peripheral blood and malignant ascites (if present) will be assayed 
using the MAINTRAC® CETC Count method by [CONTACT_826775] .  
3. Clonogenicity of C ETCs in peripheral blood and malignant ascites (if present) will be measured 
using the MAINTRAC® Tumour Sphere Units assay by [CONTACT_826775] . 
4. Expression of stem cell markers in the isolated c olonies  will be measured using fluorescein 
isothiocyana te-labelled (FITC -labelled) or alternatively labelled antibodies and scanning 
fluorescent microscopy techniques.  
Criteria for E valuation  
Pharmacokinetics:  
Pharmacokinetic samples will be collected at the time points indicated in the proposed PK schedule for 
each subject:  
At each of the sampling periods a blood sa mple will be collected into a 4 mL dipotassium 
ethyllenediaminetetraacetic acid (EDTA) tube and the sample processed to plasma. The plasma samples 
will be divided into a primary and back u p sample and stored frozen at -80°C. The primary sample will 
subsequently be shipped to the contracted bioanalytical laboratory. The samples will subsequently be 
analysed for TRX -E-002-1 using a liquid chromatography tandem mass spectrometry ( LC-MS/MS ) 
based method which has been previously validated for determination of TRX -E-002-1 concentration in 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 16 of 92 human plasma.  
Efficacy : 
Although disease response is not the primary endpoint of this study , patients with measurable disease 
will be assessed for disease  respo nse by [CONTACT_826776] 1.[ADDRESS_1146991] their disease burden evaluated at baseline and re -evaluated every 6  weeks . 
Response and progression will be evaluated in this study using the international criteria proposed by [CONTACT_826777] (RECIST) committee , version 1.1 ; the Gynecological 
Cancer Intergroup (GCIG) response criteria that incorporates CA -[ADDRESS_1146992] version 1.1, the patient’s entire tumour burden will be documented at 
baseline and followed throughout the study  as well as CA -[ADDRESS_1146993]-treatment disease  evaluation, will 
be considered evaluable for disease  response.  
Safety:  
Physical examination, vital signs, laboratory tests, including urinary analysi s, 12 -lead electrocardiograms 
(ECGs ), and AE monitoring.  
Statistical M ethods  
Determination of  sample size:  
For this Phase I dose -escalation study to determine the MTD of Cantrixil as a monotherapy and to 
investigate the safety and tolerability when  combined with standard chemotherapy, an appropriate 
sample size is not statistically determined.  
The dose -escalation Part A/ Cycle 1 of the study is designed to determine the MTD of Cantrixil as a 
monotherapy in patient s with ovarian cancer. The planned d ose levels include 0.24, 0.6, 1.25, 2.5, 5, 10  
and 20 mg/kg. From the initial dose level, single patient cohorts will be used until an AE is observed 
during Part A/ Cycle 1 that meets the definition of a DLT or warrants further examination in the opi[INVESTIGATOR_826742]/B and then the dose escalation will follow the 3+[ADDRESS_1146994] chemotherapy through Cycles 3 to 8 in Part A of 
the study. Patients who haven’t experience d a DLT but who do not complete Cycle  1 of therapy will be 
replaced. To establish the MTD in Part A of the study, up  to 42 patients will be enrolled. An expanded 
cohort with 12 patients will be enrolled and treated at the MTD in Part B of the study.  
The total sample size may be up to 54 patients (up to 42 in Part A  and 12 in Part B) enrolled into this 
study.   
Analysis  populations:  
Maximum Tolerated Dose (MTD) population: The MTD population will include all patients who 
experienced DLTs in Cycle 1 /Part A, and those who received all three weekly doses of study treatment  
in Cycle 1 /Part A. The safety, tolerability and MT D data sets regarding the Cycle 1 /Part A will be used 
to determine MTD from this analysis population.  
Safety (SAF) population: The SAF population will include all enrolled patients who receive at least one 
dose of study treatment . All safety analyses will  be conducted on this population.  
Pharmacokinetic (PK) population: The PK population will include all SAF patients who have had at least  
one PK assessment. All PK analyses will be conducted on this population.   
Intent -to-Treat (ITT) population: The ITT p opulation will include all enrolled patients who receive at 
least one dose of study treatment  and from whom at least one post -baseline efficacy measurement is 
obtained. All efficacy analyses will be conducted on this population and will be based on the act ual dose 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 17 of 92 level/single -weekly or twice weekly doses of Cantrixil at which each patient has been treated.  
Statistical Analysis:  
As appropriate, variables will be summarised descriptively (frequency and percent will be summarised 
for categorical variables; mean, standard deviation [SD], median, minimum, and maximum will be 
presented for continuous variables) by [CONTACT_218763] , including dose group  and 
monotherapy vs combination therapy . All study data will be listed by [CONTACT_1130].  
MTD  
For determination of the MTD, individual subject data from the Part A/ Cycle 1 dose escalation part will 
be reported.  
In addition, for the final statistical analys is, the following will be analys ed: 
• At each dose level, the number and proportion of su bjects in the DLT population who 
experience a DLT during the first DLT evaluation period  (Cycle 1/Part A) . 
• At each dose level, the number and proportion of treatment -emergent AEs ( TEAEs ) 
experienced by [CONTACT_826778]  
(Cycle  1/Part A) . 
The MTD will be determined according to the dose -escalation plan described above . 
The MTD is defined as the highest dose level at which no more than [ADDRESS_1146995] out of 6 subjects treated in 
a cohort and evaluable for DLT det ermination experiences a DLT  during Part A/ Cycle 1 . 
Safety and tolerability  
Adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) and 
will be summarised by [CONTACT_1196] ( SOC ), Preferred Term, and dose cohort. S everity of AEs 
will be graded using the National Cancer Institute ( NCI)-CTCAE v ersion 4.[ADDRESS_1146996] chemotherapy 
medications will be separately summarised by [CONTACT_42376]. Safety laboratory tests and vital signs 
assessments, will be summarised by [CONTACT_826779], as 
approp riate.  
DLTs, safety and tolerability data will be summarised for Cycle s 1 to 2 and Cycle s 3 to 8 separately at 
MTD from Part A and Part B study, as appropriate. A detailed Statistical Analysis Plan (SAP) including 
dictionaries used for coding and software used will be finali sed prior to clinical database lock of the 
study.  
Pharmacokinetic P arameters  
Summary statistics will be presented for Cantrixil ( TRX -E-002-1) plasma concentrations at each 
scheduled time point by [CONTACT_42376] (for example, mean, geometric mean, median, SD, standard error of 
the mean [ SEM ], coefficient of variation [ CV] and range). Summary statistics will also be presented by 
[CONTACT_826780]-E-002-1 PK parameters, including  
• Area under the plasma concentration -time curve from time zero to the last quantifiable 
concentration ( AUC 0-last), 
• Maximum plasma concentration ( Cmax) and 
• Time to maximum plasma concentration  (tmax), plus if estimable:  
• Area under the plasma concentration -time curve from time zero extrapolated to infinity 
(AUC 0-∞), 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 18 of 92 • Apparent terminal half -life (t1/2), 
• Clearance  (CL) and  
• Volume of distribution ( Vd).  
All concentrations below the limit of quantification and/or missing data will be labelled as such in the 
concentration data listings. Concentrations below the limit of quantification which are after C max will be 
treated as missing in summary statistics and for the calculation of PK parameters. Pharmacokinetic 
param eters will be determined by [CONTACT_364397] -compartmental pharmacokinetic analyses using 
Phoenix  64 WinNonLin software.  
The PK assessment results will be described in a PK study report prepared by [CONTACT_826781].  
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: [ADDRESS_1146997]  Aspartate aminotransferase  
ATC  Anatomic Therapeutic Chemical (system)  
AUC  Area under the plasma concentration -time curve  
AUC 0-∞ Area under the plasma concentra tion-time curve from time zero 
extrapolated to infinity  
AUC 0-last Area under the plasma concentration -time curve from time zero to 
the last quantifiable concentration  
BRCA  Breast cancer susceptibility gene  
CA-125 Cancer antigen 125  
CD44+ve  Ovarian cancer stem -like cells  
CD44 -ve Ovarian somatic cancer cells  
CETC Circulating epi[INVESTIGATOR_826743]/B  Data Safety Monitoring Committee/Board  
ECG  Electrocardiogram  
ECOG  Eastern Cooperative Cancer Group  
eCRF  Electronic case report form  
EDC  Electronic data capture  
EDTA  Ethylenediaminetetraacetic acid  
EU GMP  European Union – Good Manufacturing Practice  
FDA  Food and Drug Administration  
FSH Follicle stimulating hormone  
GCP  Good Clinical Practice  
GI Gastrointestinal  
GMP  Good manufacturing practice  
Hb Haemoglobin  
HBsAg  Hepatitis B surface antigen  
HIV Human immunodeficiency virus  
IB Investigator’s brochure  
IC50 Median inhibitory concentration  
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: [ADDRESS_1146998]  
ITT Intent to treat  
IV Intravenously  
LC-MS/MS  Liquid chromatography tandem mass spectrometry  
LDH  Lactate dehydrogenase  
Max Maximum  
MedDRA  Medical dictionary for regulatory activities  
Min Minimum  
MRI  Magnetic resonance imaging  
MTD  Maximum tolerated dose  
NOAEL  No observed adverse effect level  
NCI National Cancer Institute  
NOEL  No Effect Level  
PK Pharmacokinetic  
OTC  Over the counter  
PFS Progression Free Survival  
PT Prothrombin time  
QC Quality control  
RECIST  Response Evaluation Criteria in Solid Tumours  
SAE  Serious adverse event  
SAF Safety (population)  
SAP Statistical analysis plan  
SD Standard deviation  
SBP Systolic blood pressure  
SEM  Standard error of the means  
SGOT  Serum glutamic oxaloacetic transaminase  
SGPT  Serum glutamic pyruvate transaminase  
SOC  System organ class  
STD10  Severely toxic dose in 10% of rats tested  
S[LOCATION_003]R  Suspected unexpected serious adverse reaction  
t½ Apparent terminal half life  
tmax Time to maximum plasma concentration  
TEAE  Treatment emergent adverse event  
ULN  Upper limit of normal  
US [LOCATION_002]  
Vd Volume of distribution  
WHO -DD World Health Organization Drug Dictionary  
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: [ADDRESS_1146999] the two main sub -populations of ovarian cancer cells, namely ovarian cancer 
stem-like (CD44+ve) cells and ovarian somatic cancer (CD44 -ve) cells. Against CD44 -ve 
and CD44+ve cells, observed median inhibitor y concentration ( IC50) values for 
TRX -E-002-1 ranged from 23  to 109 nM.  
TRX -E-002-1 induces cell death by [CONTACT_826782] -dependent and caspase -independent 
apoptosis. The molecular target remains unconfirmed, but similar to  other drugs of this 
class and base d on in silico  modelling, it may involve tumour -associated NADH oxidase 
(ENOX 2) and disruptions to trans -membrane electron -transport mediated energy 
production (Brown et al., 2008). Recent mechanistic studies in ovarian cancer 
demonstrated that TRX -E-002-1 induces caspase -mediated apoptosis.  All pro -apoptotic 
factors (Bax, bid, XIAP) were up -regulated along with significant up -regulation of pJun, 
suggesting activation of stress pathways associated with mitochondrial depolarisation. 
Akt was unaffected.  
The s uper-benzopyran family of drugs, including TRX -E-002-1, is derived from a family 
of naturally occurring plant diphenolic (benzopyran) compounds, (i.e. , genistein and 
daidzein). Compounds such as genistein are plant hormones with pleiotropic 
characteristics  in plants and can up- and down -regulat e a range of enzymes and gene 
transcription factors. Similarly, benzopyrans have proven to have a wide range of 
pleiotropic effects in animals including humans and have been the subject of drug 
development programs ac ross various cancer and degenerative disease indications.  
Pharmaceuticals in this class include Phenoxodiol, Triphendiol and two further 
investigational agents, ME -[ADDRESS_1147000] decade. No significant safety issues were identified with Phenoxodiol in over 
800 patients treated w ith the drug either orally or intravenously (IV) on a continuous basis 
for periods up to several years (Fotopoulou et al., 2014) . However, the Phase III study for 
this agent failed due to a deficit in bioavailability of the oral formulation adopted 
(Fotopo ulou et al., 2014) . Triphendiol, selected because of its better bioavailability in 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 22 of 92 animals (Saif et al., 2009; Wang et al., 2011), was subjected to one Phase Ia clinical trial 
in Australia. This pharmacokinetic  (PK)  study showed  that the compound underwent  
extensive liver metabolism in humans, producing a demethylated metabolite (ME -143) 
which  in vitro  studies found to be a significantly more potent anti -cancer agent.  
Commencing in 2009, Kazia Therapeutics Limited  embarked on a drug discovery 
program seeking to achieve greater complexity of structure of its benzopyran drug 
technology platform. The progression in structural complexity from phenoxodiol, to 
triphendiol and then to ME -344 had resulted in progressive log -fold increases in anti -
cance r activity. Along with that increased potency came subtle changes in the molecular 
target, with phenoxodiol causing caspase -dependent apoptosis, triphendiol and ME -143 
causing both caspase -dependent and -independent apoptosis, and ME -344 killing cancer 
cells by [CONTACT_826783].  
A breakthrough in manufacturing technology, allowed the creation of benzopyrans of 
considerably greater complexity not previously possible , resulting in a new family of 
compounds with a 1 to 2 log -fold increase in anti -cancer potency compared to the earlier 
“simple” benzopyrans such as ME -344. This increase in anti -cancer potency is believed 
to come from an increase in the electron -transferring potential of the molecule, with both 
stronger electron donating and receiving activi ty. Such changes are well recognised as 
leading to stronger drug -target interactions.  TRX -E-002-[ADDRESS_1147001] of this 
“superbenzopyran” family of molecules to enter clinical research.  
 
4.1.[ADDRESS_1147002] i n a stringent mouse model of human ovar ian 
cancer. The model is one where human CD44+ve cells are formed into spheroids and then 
injected intraperitoneally  into athymic mice. This is a highly aggressive model where the 
spheroids form detectable tumours wit hin [ADDRESS_1147003] has been 
demonstrated at doses of 50  and 100  mg/kg administered daily and also at 150  mg/kg 
administered three times a week . Cantrixil is non -irritant when dosed via the 
intraperitoneal  route in this model.  
Cantrixil was also shown to be effective in a mouse model of recurrent 
chemotherapy -resistant ovarian cancer. In this model, mice were inoculated with human 
ovarian cells, tumo urs were allowed to establish, and the mice were then treated with 
standard chemotherapy (paclitaxel). While initially responding to chemotherapy, tumours 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: [ADDRESS_1147004] to those mice treated with taxol, when mice with 
chemo -resistant tumours were treated with Cantrixil their growth was significantly 
inhibited. These data confirm that Cantrixil is active in a model of recurrent ovarian 
cancer where tumours are resistant to both cisplatin and paclitaxel and demonstrates the 
potential of Cantrixil for treating both therapy naïve and chemotherapy -resistant  ovarian 
cancer in the clinic.  
Absorption, distribution, metabolism, and excretion (ADME) studies i n healthy rats 
indicated that after intraperitoneal administration of a single dose of Cantrixil, 
TRX -E-002-1 had a relatively short half -life (time to maximum plasma concentration 
[tmax] = 0.5 to 2 hours and apparent terminal half -life [t 1/2] = 2 to 3 hou rs) and was present 
in plasma and tissue predominantly in the parent, unconjugated form. High levels were 
observed in kidneys, pancreas, stomach, large intestine, adrenals, ovaries and skin 
although this was largely eliminated at 24 hours after exposure fr om all tissues except the 
large intestine. The drug was eliminated via both renal and hepatic routes in rats. A 
similar ADME profile was observed in dogs, except that it was cleared from the large 
intestine at 72  hours and while circulating TRX -E-002-1 was  predominantly in the parent 
unconjugated form, it was conjugated in the tissues. In dogs and rats , following 14 -day 
repeat exposure , there was no evidence indicating accumulation of TRX -E-002-1 with 
multiple dosing.  
Escalating dose studies indicated that  the maximum tolerated dose ( MTD ) following a 
single dose of Cantrixil was 50  mg/kg in male and female rats. Based on a [ADDRESS_1147005] Level (NOAEL) was 
observed to be 3 mg/kg for male rats and 10 mg/kg for female rats and the No Effect 
Level (NOEL) was 0.5  mg/kg for both male and female rats.  
Dogs appeared to tolerate higher doses of Cantrixil than rats, with single doses up to 
80 mg/kg being administered without obvious clinical signs of toxic ity. The MTD for 
dogs was considered to be greater than 200  mg/kg for a single dose of Cantrixil. A 28 -day 
repeat dosing study concluded that the NOAEL for male and female dogs together was 
10 mg/kg. In both species , there was a gender specificity in toler ance to Cantrixil.  
In both species  (i.e., rats and dogs) , clinical signs included lethargy, discoloured faeces, 
liquid/soft faeces, soft faeces and emesis. Necropsy and histological test article -related 
observations were most prominently seen in the gastr ointestinal  (GI) tract with red 
streaking a common observation. These GI toxicities resolved during the [ADDRESS_1147006] on 
spermatogenesis and these effects did not completely resolve  during the 14 -day recovery 
period. Electrocardiogra m (ECG) readings in dogs showed no effect of Cantrixil on the 
QT interval. Mild changes in blood pressure, heart rate and body temperature were 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 24 of 92 observed immediately following dosing but these parameters r eturned to normal within 
hours of dosing.  
Further information can be found in the Investigator ’s Brochure (IB)  (Cantrixil 
Investigator’s Brochure ). 
4.[ADDRESS_1147007] of this new “super” benzopyran drug family to reach the clinical 
research stage of development and is designed for intraperitoneal  delivery. 
Pharmacokinetic studies have shown that intraperitoneal  administration of chemotherapy 
resul ts in a [ADDRESS_1147008] a significantly longer half -life than drugs given intravenously  
(Gou rley et al., 2016) . Based on the body of evidence in the literature (now 8 randomised 
clinical trials ) (Jaaback et al., 2011) , the National Cancer Institute (NCI) encourages the 
use of a combined IV and intraperitoneal chemotherapy regimen for ovarian canc er 
patients (Trimble and Alvarez 2006) . Although intraperitoneal  regimens resulted in 
higher rat es of toxicity compared with IV , the evidence suggests that the benefits of 
intraperitoneal  delivery outweigh the risk, with overall survival for women with adv anced 
ovarian cancer extended by [CONTACT_2902] 1 year (Walker 2013; Tewari et al., 2015) . 
The unequivocal and reproducible efficacy of Cantrixil in mouse models of ovarian 
cancer and the relative tolerance of Cantrixil in both rodent and non -rodent animals, 
warran ts further development of this drug candidate. The anti -tumour effect in a mouse 
model has been demonstrated at doses of 50  and 100  mg/kg administered daily and also at 
150 mg/kg administered three times a week . Cantrixil is non -irritant when dosed via the  
intraperitoneal  route in this model. This Phase I study represents the next step in the 
clinical development program for Cantrixil. In this study, initially the drug will be 
delivered as a single agent in order to identify the MTD  as a monotherapy. Safety  and 
tolerability profiles of Cantrixil in humans will be investigated as well as the drug’s PK 
profile when delivered as a single agent. Once tolerance as a monotherapy has been 
established, the safety of Cantrixil as part of a combination therapy with st andard 
chemotherapy agents will be examined. An initial assessment of the potential benefits of 
the drug will also be examined using tumour imaging and biomarkers to assess 
anti-cancer activity.  
The starting dose of Cantrixil of 0.24 mg/kg has been chosen based on the animal 
toxicology data. A common approach for many small molecules is to set the start dose at 
1/10 the severely toxic dose in 10% of the animals (STD 10) in rodents (Senderowicz, 
2010). In light of the good tolerance of this molecule in mice and dogs, as well as the 
MTDs determined in recent human clinical trials for related compounds (ME -344 and 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 25 of 92 ME-143; Bendell et al., 2014, Pant et al., 2014 ), the starting dose has been set at 1/10 th 
the observed STD10 in rats. The human equivalent dose is 0.24 mg/kg, calculated using 
standard species conversion tables (FDA Guidance 2005) and adding a safety factor of 
10. This starting dose is around ten -fold less than the starting dose in humans fo r ME -143 
(2.5 mg/kg) and ME -344 (1.25mg/kg)  (Bendell et al., 2014; Pant et al., 2014) . 
This study will be performed in compliance with the protocol, International Council for 
Harmonisation ( ICH) Good Clinical Practices ( GCP ) and applicable regulatory 
requi rements. Aspects of the study concerned with the investigational medicinal 
product(s) (IMPs) will meet the requirements of European Union ( EU) and Food and 
Drug Administration (FDA) Good Manufacturing Practices ( GMP ). 
4.[ADDRESS_1147009] been undertaken. Some of the c linical signs  
observed in these studies included lethargy, swe lling of the abdomen, discoloured faeces, 
liquid/soft faeces, and soft faeces. Necropsy and histological study drug -related 
observations were most prominently seen in the gastrointestinal tract and male 
reproductive organs.  ECG readings in dogs showed no effect of Cantrixil on the QT 
interval.  
Preliminary data from experiments in human hepatic microsomes indicate that 
TRX -E-002-[ADDRESS_1147010] to their health or 
safety. If such measures are taken the Sponsor shall immediately (no later than 3  days 
from the date the measures are taken) give written notice to the licensing authority and 
the relevant Ethics Committee  of the measures taken and the circumstances giving rise to 
those measures . 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 26 of 92 The Sponsor will immediately notify the Principal Investigator  [INVESTIGATOR_340710].  
5 STUDY OBJECTIVES  
5.1 Primary Objective s 
• To determine the MTD of Cantrixil when delivered as a single agent , administered 
intraperitoneally , at a weekly administration frequency .  
• To evaluate the safety and tolerability of Cantrixil delivered via intraperitoneal  
administration as a single agent and in combination with standard chemotherapy , 
when administered weekly . 
• To characterise the PK of intraperitoneal  Cantrixil when delivered as a single 
agent and in combination with standard chemotherapy.  
5.2 Secondary Objecti ves 
• To evaluate the progression free survival  (PFS). 
• To evaluate the time to paracentesis and the volume of malignant ascites drained 
at each paracentesis event (for those patients with malignant ascites).  
• To evaluate the potential anti -cancer  activity of Cantrixil using Response 
Evaluation Criteria in Solid Tumours (RECIST) criteria, version 1.1 and CA -125 
measurements . 
• To evaluate the change in cancer antigen 125 ( CA-125) in peripheral blood before 
and after treatment with Cantrixil.  
5.3 Exploratory Objectives  
• To evaluate the safety, tolerability, PK, and activity of Cantrixil when 
administered intraperitoneally as a single agent and in combination at a twice 
weekly administration frequency  
• To evaluate the change in the number of circulati ng epi[INVESTIGATOR_826737] 
(CETCs) in peripheral blood and malignant ascites (if present) before and after 
treatment  with Cantrixil . 
• To evaluate the clonogenicity of C ETCs in peripheral blood and malignant ascites 
(if present) before and after treatment  with Cantrixil . 
• To evaluate the expression of stem cell markers, CD44 and ALDH, in c olonies  
isolated in the clonogenicity assays.  
 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 27 of 92 6 INVESTIGATIONAL PLAN  
6.1 Overall Study Design  
This study is a progressive design with 3 discrete Parts (Part A: Dose escalation  and Part 
B: Dose expansion ). The overall study schema is presented in Figure 1.  
Cycle 1/ Part A is a dose -finding assessment (dose escalation) to establish the MTD of 
Cantrixil when administered as a single dose once a week  for 3 weeks. Cycle 2/Part A 
continues with 3 additional weekly doses of Cantrixil as a monotherapy before an 
assessment of disease response . In Cycles 3 to 8/Part A patients will be admini stered the 
same once -weekly dose of Cantrixil they tolerated in Cycle s 1 and 2  (tolerance defined as 
no dose limiting toxicities [ DLTs ] or unacceptable adverse events [AEs] ) in combination 
with a standard chemotherapy agent, in order to assess the safety and tolerability o f 
Cantrixil in combination therapy. Standard chemotherapy drugs will be administered at 
the standard efficacious doses to maintain optimum benefit of known drug combinations 
for p atients. Treating physicians may choose the combination therapy from the list in 
Table 1 taking into consideration factors such as pre -existing comorb idities, prior 
toxicities and responses as well as patient and physician preferences.  
 
Table 1 Permitted Combination Therapi[INVESTIGATOR_826744] 4 over 1 h on Day 4 every 21 d for six cycles  Dizon et al., 2015  
Liposomal doxorubicin 40 -50 mg/m  2 IV over 30 min on Day 4 every 
21 d  Gordon et al., 2004  
Gemcitabine 1000 mg/m² IV over 30 min on Days 4 and 11 (Parts A 
and B); every 21 d   Markman et al., 2003  
Paclitaxel 80 mg/m  2 IV over 1 h weekly on Days 4, 11 and 18 (Parts A 
and B)  Markman et al., 2006  
Docetaxel 75 -100 mg/m  2 IV over 1 h on Day 4 every 21 d  Rose et al., 2003  
Topotecan 4.0 mg/m2 on Days 4, [ADDRESS_1147011] be diligently recorded in the patie nts’ electronic case 
report form (eCRF).  
Once the MTD has been determined in Part  A/Cycle 1 , an additional 12  patients will be 
recruited in an expansion cohort for Part B. These patients will receive 2 cycle s of 
Cantrixil monotherapy at the MTD, followed by [CONTACT_8622] 6 cycles of combination therapy.  
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: [ADDRESS_1147012] not be shorter than 7 days. For other intraperitoneal 
access devices, the period may be shorter if adequate stability and/or healing of the 
delivery system’s insertion site is confirme d by [CONTACT_1963].  
Patients should begin protocol treatment within a maximum of 28 days of enrolment (i.e., 
signing of consent form).  
Patients will start at Dose Level 0 (see  Table 2) which is calculated to be the human 
equivalent of 10% of the STD10 dose in rats (dose is 1/10 the severely toxic dose in 10% 
of rats tested). Single patient cohorts will be treated with increasing doses of Cantrixil 
until an AE  is observed  during Part A/Cycle 1 that meets the definition of a DLT or , in 
the opi[INVESTIGATOR_826745]/Board (DSMC/B) and the 
Investigator, warrants observing additional patients at this dose level; at this point the 
study will rev ert to a 3+3 rules -based dose escalation study (see Section  6.1.2 ). The 
decision to expand from single patient cohorts to 3 patient cohorts is crit ical for the safety 
of participants and will be made with input from the Investigator and DSMC/B  
responsible for this study (see Section 6.1.1 ). Dose levels -1 and -2 will only be activated 
if there are 2 DLTs at Dose Level 0 and -1, respectively . Once the study enters a 3+3 
rules -based design, the study will not revert back to single patient cohorts.  
Table 2 Doses at each Dose Level  
Dose Level  Cantrixil  Patient Number  
Level -2 0.06 mg/kg  
Dose is half of Level -1 n = 2 to 6  
Level -1 0.12 mg/kg  
Dose is half of Level 0  n = 2 to 6  
Starting dose:  
Level 0  0.24 mg/kg  
Dose is equivalent to 10% of STD10  n = 1 to 6  
Level 1  0.6 mg/kg  
Dose is 2 .5 x Dose Level 0  n = 1 to 6  
Level 2  1.25 mg/kg  
Dose is 2 .1 x Dose Level 1  n = 1 to 6  
Level 3  2.5 mg/kg  
Dose is 2 x Dose Level 2  n = 1 to 6  
Level 4  5.0 mg/kg  
Dose is 2 x Dose Level 3  n = 1 to 6  
Level 5  10.0 mg/kg  
Dose is 2 x Dose Level 4  n = 1 to 6  
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 29 of 92 Level 6  20.0 mg/kg  
Maximum dose to test  n = 1 to 6  
STD10: Severely toxic dose in 10% of rats tested  
If any of the following unacceptable AEs or DLTs are observed and unless clearly 
unrelated to study treatment (e .g., disease progression), treatment at the currently 
allocated Cantrixil dose will be be paused. At this point a dose reduction may be 
considered or the treatment may be terminated, depending on what is considered by [CONTACT_826784]’ s best interest . 
• Hematologic toxicity  
o Grade [ADDRESS_1147013] 5 days , 
o Grade 3 or Grade 4 neutropenia associated with fever >38.5°C ,  
o Grade [ADDRESS_1147014] 5 days ,  
o Grade 3 thrombocytopenia associated with severe bleeding i n the opi[INVESTIGATOR_18959] , 
o Dose delay of ≥3 weeks due to failure to recover counts . 
• Any Common Terminology Criteria for Adverse Events (CTCAE) version  4.03 
Grade 3 or Grade 4 non -haematological toxicity except:  
o Alopecia , 
o Grade 3 abdominal pain deem ed related to the port  or catheter  as 
determined by [CONTACT_1963] , 
o Grade 3 anorexia , 
o Grade 3 fatigue , 
o Grade 3 nausea and/or vomiting, or diarrhoea , lasting ≤48 hours with o r 
without maximal medical management , 
o Grade 3 dehydration as a result of na usea and vomiting , 
o Grade 3 constipation , 
o Grade 3 metabolic abnormalities [ hypokalaemia , hypomagnesemia, 
hypocalcaemia , hypophosphatemia]) that recovers to Grade 1 or less 
within 48 hours with or without medical management , 
• Other serious adverse events whic h, in the opi[INVESTIGATOR_80021] , 
necessitate temporary or permanent cessation of administration , 
• Treatment delays of ≥3 weeks due to any non -haematological toxicity will 
constitute a DLT . 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: [ADDRESS_1147015]  
chemotherapy at their discretion and if it is considered safe and in the patient’s best 
interest.  
All patients who discontinue from the study treatment (i.e. are now Off Therapy/End of 
Therapy) will prog ress to follow -up unless the patient withdraws consent.  
The initiation of each new cycle of Cantrixil will be at the discretion of the Investigator 
and will depend on the potential or measurable benefit to the patient assuming continued 
tolerability  and a dequate organ function . 
Cantrixil treatment will also be stopped due to RECIST version 1.[ADDRESS_1147016] version 1.1 criteria 
but who, in the opi[INVESTIGATOR_125362], continue to derive clinical benefit , may 
continue treatment. Patients may also be discontinued from study treatment if the 
Investigator considers continuing therapy is not in the patient’s best interest.  
All patients discontinued from study treatment (i.e. are now Off Therapy/End of Therapy) 
will progress to follow -up unless the patient withdraws consent.  
Tumour assessment via radiological imaging will be conducted during screening and 
every [ADDRESS_1147017] -enhanced magnetic resonance imaging (MRI) or contrast -
enhanced computed tomography (CT) may be used, but once a modality is  used at 
baseline this must be used consistently for that patient throughout their participation on 
the study. Other imaging is not mandatory, but may be performed if clinically indicated.  
Adverse events will be monitored for the duration of the study from the time of informed 
consent. Blood samples will be collected weekly for standard safety testing, or more 
frequently if clinically relevant, during the study. Additional volumes of blood will be 
collected before and after administration of Cantr ixil for PK analysis (4 mL per time point 
as per the proposed PK schedule [ Table 5] and for any exploratory studies (at baseline, 
end of Cycle s 2, and End of Therapy  - 15 to 20 mL at each time -point).  
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 31 of 92 Part A  (Dose escalation of Cantrixil as a monotherapy ):  
Cycle 1  
Following placement of a port or catheter, eligible  patients will be administered a single 
intraperitoneal dose of the study treatment  Cantrixil (TRX -E-002-1 formulated  in 
Dexolve -7) once a week for 3  weeks. Patients will be monitored for DLTs over the 
21-day cycle (Cycle 1).  
Blood samples will be collected weekly at each scheduled visit for standard safety testing, 
or more frequently if  clinically relevant. Results of the safety assessments must be 
available prior to Cantrixil administration to ensure that all assessments still meet the 
inclusion  criteria as described in Section 6.2.1  and it is safe to proceed to the next dose of 
treatment. Treatment delays of up to three weeks are allowed for recovery without being 
classified as a protocol deviation or a dose limiting toxicity . 
Patients will continue to be monitored until they meet the off -study criteria  (see below)  
but will only be evaluable for DLTs that define the MTD of Cantrixil as a monotherapy 
during Cycle  1/Part A .  
Patients will start at Dose Level 0 (see  Table 2) which is calculated to be the human 
equivalent of 10% of the STD10 dose in rats (dose is 1/10 the severely toxic dose in 10% 
of rats tested). S ingle patient cohorts will be treated with increasing doses of Cantrixil  
until an AE is observed during Part A/Cycle 1 that meets the definition of a DLT  or, in 
the opi[INVESTIGATOR_557182]/B and the Investigator , warrants observing additional patients at 
this dose level; at this point the study will re vert to a 3+3  rules -based dose escalation 
study  (see Section 6.1.2 ). The decision to expand  from single patient cohorts to 3 patient 
cohorts is critical for the safety of participants and will be made with input from the 
Investigator  and DSMC/B  responsible for this study  (see Section 6.1.1). Dose levels -1 
and -2 will only be activated if there are 2  DLTs at Dose Level 0  and -1, respectively . 
Cycle 2 
Patients that are still on study treatment at the end of Cycle 1/Part A will receive another 
cycle of Cantrixil monotherapy with once weekly dosing before disease assessment. Note 
that a disease assessment will be conducted at the end of monotherapy but patients will 
not au tomatically be removed from therapy at this time -point if they have progressive 
disease as defined by [CONTACT_44993] 1.[ADDRESS_1147018] not discontinued from the study at the end of Cycle 2 will proceed to 
Cycles 3 to 8/Part A of the study .  
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 32 of 92 Cycles  3 to 8 (Cantrixil in Combination with Standard Chemotherapy)  
Patients that progress to Cycles 3 to 8/Part A  will continue on the same dose level of 
Cantrixil that they tolerated in Cycle s 1 and 2 /Part A  but in combination with a systemic 
chemotherapy selected from Table 1 for the patient by [CONTACT_1963]/Investigator. 
In the rare event that there does not exist a combination chemotherapy that c ould be 
recommended by [CONTACT_737], patients may continue to Cycles 3 to 8 receiving 
Cantrixil as a monotherapy if it is deemed by [CONTACT_826785] a monotherapy .  
During Cycles 3 to 8/Part A , patients will be administered Cantrixil once per week for 
each 21 -day cycle. The combination chemotherapy will be administered as per the 
schedules in Table 1. Before administration of the combination chemotherapy, the PK 
results for each patient from Part A/ Cycle [ADDRESS_1147019] be 
diligently recorded in the patient’s eCRF.   
Part B (Expansion Cohort at MTD) : 
Once the MTD has been established  in Part A/Cycle 1 , an expansion cohort will be 
recruited at the MTD. An additional 12 patients will be recruited in this cohort on top of 
those recruited in Part  A at the MTD. These patients will be subjected to the same 
intervention described above with 2 cycle s of monotherapy followed by [CONTACT_8622] 6 cycles of 
combination therapy . 
Continued Access for Patients:  
All patien ts who complete eight cycles, and in whom the local Investigator feels there has 
been a clinical benefit from treatment, may continue to receive Cantrixil, following 
discussion with the Sponsor. Those patients granted continued access will be dosed 
weekly with Cantrixil at the dose that they have been receiving during cycles [ADDRESS_1147020] data on adverse events, 
Cantrixil administration and drug accountability . Cantrixil treatment will be stopped due 
to locally  defined disease progression, recurrence of an unacceptable toxicity after 1 
Cantrixil dose reduction or patient consent withdrawal. The definition of unacceptable 
toxicity during this extended access period is the same as defined in section 6.1.3. 
Patients may also be discontinued from study treatment if the Investigator considers 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 33 of 92 continuing therapy is not in the patient’s best interest. When dosing of Cantrixil is 
discontinued, the Off Therapy/End of Therapy schedule of assessments in Table 4 should 
be conducted. All patients discontinued from study treatment (i.e. are now Off Ther apy/ 
End of Therapy) will progress to follow -up unless the patient withdraws consent.  
It is at the discretion of the Investigator whether this continued treatment is a maintenance 
monotherapy or a combination chemotherapy.  
All patients that are provided continued access to Cantrixil must agree to on -going data 
collection for monitoring safety, progression and survival.  
. 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeuti cs Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 Page 34 of 92 Figure 1 Proposed Dosing Schema  
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
  
   
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
  
  
  
  
  
  
  
    
Car
Dox3
DayWeek
Topotecan 4.0 mg/m2 IV over 1 h on Days 4, 11 and 18 (Part A and B)DocGreen arrow indicates visit includes full safety assessment before administration of therapy, as 
per table of assessments
Blue arrows represent visits where only the collection of 24-hour PK blood samples occurs; only 
in certain cycyles, see PK collection schema. 
Red arrow indicates visit includes a full safety assessment PLUS a decision to continue to next 
cycle based on tolerability and potential benefit. Day 22 may coincide with Day 1 of the next 
cycle. A tumour assessment may be conducted on this day as per the schedule of assessments. 
Purple arrow indicates that a visit may be scheduled for the administration of the combination 
chemotherapy. A visit will be scheduled if a coloured box appears in the column for the 
combination chemotherapy that has been selected for the patient.
Dose of Cantrixil administered IP according to starting dose allocated upon enrolment. Cantrixil 
is administered once weekly on Days 1, 8 and 15 for Parts A and B. The dose that any individual 
patient receives will not be escalated; it will either remain the same as the starting dose or may 
be de-escalated by [CONTACT_30560]. 
Combination therapy options and scheduling are described below (weeks 3 - 8). Ctx may be continued as a 
monotherapy or in combination with one of the below chemotherapeutic options. The decision to progress to 
combination and the chemotherapy added to treatment will be decided by [CONTACT_1963]. The shading color 
below is repeated in the table above to indicate days on which visits will be required to follow an appropriate 
treatment schedule. In all options, the black arrow indicates continued weekly Cantrixil treatment. 
Carboplatin AUC4 over 1 hour on Day 4 (Part A and B) 
Liposomal Doxorubicin 40 - 50 mg/m2 IV over 30 min on Day 4 (Part A and B) 
Gemcitabine 1000 mg/m2 IV over 30 min on Days 4 and 11 (Part A and B) 
Paclitaxel 80 mg/m2 IV over 1 h weekly on Days 4, 11, and 18 (Part A and B) Ctx ()
Topo3 to 8
Gem
PacWeek 1 2 3

Doc+ CtxGem + Ctx
Pac+ Ctx
Docetaxel 75 - 100 mg/m2 IV over 1 h on Day 4 (Part A and B) Cycle 1 to 2
2NVGN-002-101 Study Schema
1
Ctx
VisitPart A and Part B
DayVisit
Cycle 
Car + Ctx
Dox + Ctx
Topo+ CtxCtx
 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 Page 35 of 92 6.1.1  Data Safety Monitoring Committee /Board  
This study will utilise a D ata Safety Monitoring Committee /Board (DSMC/B)  throughout 
the study . The membership and governance of this committee are outlined in a separate 
charter. The D SMC/B  will review safety data from each patient at the end of each Part 
A/Cycle  1 to confirm that it is safe to dose escalate  and to assess the compatibility of the 
proposed combination therapy  schedule . Written confirmation from the DSMC/B  will be 
required before a patient can be administered a higher dose than the previously enrolled 
patient  or proceed to combination therapy . 
An appropriate interval will separate the investigation of dose levels to per mit a timely 
review and evaluation of safety, tolerability and PK  data prior to proceeding to a higher 
dose level.  
All data reviewed at the DSMC/B meeting (safety, tolerability and PK where appropriate) 
will be subjected to a quality control (QC) review.   
The DSMC/B  will continue to assess safety data throughout the course of the study, and 
may discontinue patient exposure to particular combinations if evidence of unacceptable 
toxicity emerges.  
 
6.1.2  Dose Escalation Criteria  
Single patient cohorts will be treat ed with increasing doses of Cantrixil until a treated 
patient exhibits an AE during Part A/Cycle 1 that meets the definition of a DLT or , in the 
opi[INVESTIGATOR_826746] D SMC/B , warrants observing additional patients at 
this dose level; at this point the study will revert to a 3+3  rules -based dose escalation 
design  (see Table 3). During the single patient cohort stages and the 3+[ADDRESS_1147021] completed Cycle 1/Part A, 
tolerability data will be evaluate d by [CONTACT_941] D SMC/B  and a decision to escalate to the next 
dose level will be made.  Once the study enters a 3+3 rules -based design, the study will 
not revert back to single patient cohorts.  
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 36 of 92 Table 3 3+[ADDRESS_1147022] 3 more patients at this dose level and  
• if 0 of these 3 new patients experiences a DLT, proceed to the 
next dose level;  
• if ≥1 of this group suffer a DLT (for a total of ≥2/6 patients with 
a DLT) , this dose exceeds the MTD and dose escalation is 
stopped. To further assess tolerability, [ADDRESS_1147023] dose level if only 3 patients were 
treated previously at that dose. Upon determination of the MTD, 
the study will proceed to Part B of the study.  
≥[ADDRESS_1147024] 
dose level if only 3 patients were treated previously at that dose and the 
study will proceed to Part B of the study.  
DLT: Dose li miting toxicity; MTD: maximum tolerated dose  
Progression to the next higher dose level will be stopped if one or more patients 
experience a DLT  (as outlined in Table 3) but also if  an AE occurs that, in the opi[INVESTIGATOR_352159]’s medical representative  and the DSMC/B , warrants 
discontinuation of dose escalation . 
 
6.1.3  Study Stoppi[INVESTIGATOR_826747] a SAE  or an 
AE, which  in the o pi[INVESTIGATOR_572059] S ponsor’s medical representative  or 
DSMC/B , warrants discontinuation of th e study treatment for that patient ’s well being .  
If any of the following unacceptable AEs or DLTs are observed and unless clearly 
unrelated to study treatment (e.g. , disease progression), treatment at the currently 
allocated Cantrixil dose will be paused. At this point a dose reduction may be considered 
or the treatme nt may be terminated, depending on what is considered by [CONTACT_826786]’s best interest. : 
  
• Hematologic toxicity  
o Grade [ADDRESS_1147025] 5 days,  
o Grade 3 or Grade 4 neutropenia associated with fever >38.5°C,  
o Grade [ADDRESS_1147026] 5 days,  
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 37 of 92 o Grade 3 thrombocytopenia associated with severe bleeding in the opi[INVESTIGATOR_18959],  
o Dose delay of ≥3 weeks due to failure to recover counts  to levels described 
in the study inclusion  criteria  as describe d in Section 6.2.1 . 
• Any CTCAE version 4.03 Grade 3 or Grade 4 non -haematological toxicity except:  
o Alopecia,  
o Grade 3 abdominal pain deemed related to the port  or cat heter  as 
determined by [CONTACT_1963],  
o Grade 3 anorexia,  
o Grade 3 fatigue,  
o Grade 3 nausea and/or vomiting, or diarrhoea, lasting ≤48 hours with or 
without maximal medical management,  
o Grade 3 dehydration because of  nausea and vomiting,  
o Grade 3 constipation,  
o Grade 3 metabolic abnormalities [hypokalaemia, hypomagnesemia, 
hypocalcaemia, hypophosphatemia]) that recovers to Grade 1 or less 
within 48  hours with or without medical management,  
• Other serious adverse events which, in the opi[INVESTIGATOR_431950], 
necessitate temporary or permanent cessation of administration , 
• Treatment delays of ≥3 weeks due to any non -haematological toxicity will 
constitute a DLT . 
All patients who discontinue from the study treatment (i.e. are now Off Therapy/ End of 
Therapy will progress to follow -up unless the patient withdraws consent.  
The occurrence of significant safety events as described above will require that further 
dosing of other patient s be evaluated by [CONTACT_46874] S ponsor’s medical 
representative to determine study discontinuation.  
6.1.4  Discussion of Study Design  
Current li terature on Phase I dose -escalation designs suggests that when the pre -clinical 
data indicate a wide therapeutic window and little expected toxicity in human patient s, it 
is very reasonable to apply an aggressive dose titration (e.g., by [CONTACT_826787] -based methods) (Le Tourneau et al., 2009) . However, if the 
pre-clinical data were less certain about how human patient s will tolerate the drug or 
predict a very narrow therapeutic window, then it would be prudent to choose a  more 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 38 of 92 conservative dose escalation scheme  (Le Tourneau et al., 2009) . Given the good 
tolerability of this class of drugs in humans as demonstrated in the clinical trials using 
Phenoxodiol, ME -143 and ME -344 (Saif et al., 2009, Pant et al., 2014)  and the ex cellent 
tolerability of Cantrixil in mice and dogs, this study will adopt a dose escalation scheme 
that is accelerated compared to the traditional Fibonacci sequence but starts at the 
conservative 10% of STD10 level.   
 
6.2 Study Population  
Patients with any s tage of persistent  or recurrent ovarian cancer, fallopi[INVESTIGATOR_826748]/exclusion criteria . 
6.2.[ADDRESS_1147027] Inclusion Criteria  
For inclusion in the study, patients ha ve to fulfil all of the following criteria:  
1. Patients must have recurrent or persistent epi[INVESTIGATOR_12253], fallopi[INVESTIGATOR_8916], or 
primary peritoneal cancer. The original diagnosis  must be verified by a histology 
report. All histological sub -types and all grades of disease are eligible to 
participate; grade, histological sub -type and breast cancer susceptibility gene 
(BRCA) status must be recorded at study entry.  
2. Patients must be female and at least [ADDRESS_1147028] -feeding and able to 
adopt adequate contraception as described in section [IP_ADDRESS]  
3. Patients with malignant ascites are eligible to participate; paracentesis will be 
conducted before the administrat ion of Cantrixil . Drainage of the maximum 
volume of ascites should be performed according to local standard operating 
procedures before administration of Cantrixil . 
4. Patients must have completed at least two (2) or more prior regimens  (including 
adjuvant th erapy) for their ovarian, Fallopi[INVESTIGATOR_826749]; all prior therapi[INVESTIGATOR_826750]. Patients that have received prior intraperitoneal therapy are eligible for 
this study. Patients should have failed standard of care drugs prior to being 
eligible to be part of the proposed study.  
5. Patients must have platinum -resistant relapsed disease, platinum refractory 
disease, or have documented intolerance to platinum therapy . Patients will not be 
eligible based on rising CA -[ADDRESS_1147029] other clinical 
symptoms (such as malignant ascites) or radiological tumour measurements 
that support disease recurrence or progression . 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: [ADDRESS_1147030] passed from any previ ous therapy (6 weeks for 
bevacizumab, nitrosoureas or mitomycin  C treatment) any toxicities from prior 
therapi[INVESTIGATOR_826751] v ersion  4.[ADDRESS_1147031] a performance status of Eastern Cooperative Oncology Group 
(ECOG) 0  to 2 and, in the Investigator’s opi[INVESTIGATOR_1649], be able to complete at least a 
major part of the study . 
8. Patients willi ng and able to undergo insertion of a port or catheter for 
intraperitoneal  access; the type of port or catheter used will be at the discretion of 
the Investigator and will be recorded.  
9. Patients with measurable or non -measurable disease  may be enrolled ; disease 
response will be measured according to RECIST version 1.[ADDRESS_1147032] or MRI  and CA -125 measurements . 
10. Patients with acceptable hepatic and marrow function as defined below:  
• Absolute neutrophil count >1.5 x 109/L without myeloid growth factor 
support . 
• Platelets >100 x 109/L. 
• Total bilirubin; <2.5 times the institutional upper limit of normal (ULN) . 
• Haemoglobin  (Hb) of >10 g/dL; patients with Hb  >9g/dL will be considered 
for this study if they have not received a transfusion or other bone marrow 
support . Patients with Hb >10  g/dL that have received a recent transfusion 
will only be eligible if there has been a wash -out period of 7 days for rhesus 
factor and 10 days for platelet transfusions, respectively .  
• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase 
[SGOT])/ alanine aminotransferase (ALT) (serum glutamic pyruvate 
transaminase [SGPT]) ≤2.[ADDRESS_1147033]  if no demonstrable liver 
metastases or <[ADDRESS_1147034] in the presence of l iver metastases .  
• Serum creatinine < 1.[ADDRESS_1147035] . 
• Prothrombin time (PT) or international normalised ratio (INR) ≤1.[ADDRESS_1147036] 
and activated partial thromboplastin time (aPTT) ≤1.[ADDRESS_1147037] if not on 
anticoagulation treatment . 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 40 of 92 11. Patients willing and able to comply wit h all study requirements, including 
treatment timing and/or nature of required assessments and treatment at 
designated study centre.  
12. Each participant must be adequately informed about the purpose of the study; 
potential benefits and risks; their right to r efuse participation or to withdraw 
consent at any time; institutional affiliation and potential competing interests of 
the researcher; and sources of study funding and have signed and dated a written 
informed consent form . 
6.2.[ADDRESS_1147038] Exclusion Criteria  
Any of  the following is to be regarded as a criterion for exclusion from the study:  
1. Patients who have had chemotherapy, targeted therapi[INVESTIGATOR_014], biologic therapy, 
immunotherapy, or radiotherapy within 4 weeks (6 weeks for nitrosoureas or 
mitomycin  C or bevacizumab ) prior to entering the study . 
2. Patients must not have had major surgery within [ADDRESS_1147039] received any other investigational medicinal products 
(IMPs) or participated in any other interventional clinical research studies  within [ADDRESS_1147040] Cantrixil administration . 
4. Patients receiving any medications or substances that are strong inhibitors or 
inducers of cytochrome P450 (CYP)1A2, CYP2B6 and CYP3A4 or those 
substances with narrow therapeutic index are not to be en rolled. These compounds 
are prohibited from screening until completion of end of therapy  or first post -
treatment follow -up visit. For a list of prohibited medications see the University of 
Indiana Clinical Pharmacology Department's P450 Drug Interaction Table 
(http://medicine.iupui.edu/clinpharm/ddis/main -table/). Note: the use of paclitaxel 
is allowed, but only 24 hours after Cantrixil administration.  
5. Patients deemed by [CONTACT_826788], including but not limited to any one or more of the 
following;   
• Patients with a r ecent h istory (previous 12 months) of bowel obstruction prior 
to study entry .  
• Patients with CT scans that suggest invasion of bowel by [CONTACT_432532] . 
• Patients with s ymptoms to suggest impending bowel obstruction .  
• Patients with p rior whole abdominal radiotherapy . 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 41 of 92 • Patients with chronic inflammatory bowel diseases such as Crohn's disease or 
ulcerative colitis . 
6. Patients may not have uncontrolled or severe systemic diseases  or psychiatric 
conditions , which in the Investigator ’s opi[INVESTIGATOR_826752]. Screening 
for chronic condi tions is not required.  
7. Patients who are pregnant, lactating, or unable to adopt adequate contraception ; 
women of childbearing potential must have a negative pregnancy test within 
[ADDRESS_1147041] tested positive for human immunodeficiency virus (HIV) . 
10. Patients with a known hypersensitivity to or a serious reaction to benzopyrans are 
excluded.  
6.2.3  Restrictions  
• All medications, both prescription and over -the-counter (OTC), taken within 
[ADDRESS_1147042] be reported and recorded on the eCRF . 
• Grapefruit and grapefruit juice are prohibited, from 1 week prior to the start of the 
study (Day 1) until the last PK sample has been collected.  
• Use of medications or substances that are strong inhibitors or inducers of 
cytochrome P450 (CYP)1A2, CYP2B6 and CYP3A4 or those substances with 
narrow therapeutic index are prohibited from screening until completion of end of 
therapy  or first post -treatmen t follow -up visit. For a list of prohibited medications 
see the University of Indiana Clinical Pharmacology Department's P450 Drug 
Interaction Table (http://medicine.iupui.edu/clinpharm/ddis/main -table/). Note: 
the use of paclitaxel is allowed, but only 24  hours after Cantrixil administration . 
• Medications which are moderate to weak P450 enzyme inducers or inhibitors (see 
list referenced above),  should  have a complete washout prior to Cantrixil 
administration and only be administered 24 hours after Cantrixil  administration. 
These medications should be used w ith caution and the I nvestigator should be 
alert for any potential unpredictable drug -drug interactions.  
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVG N-002-101 
IND Number: 123275  
 
 
 
 Page 42 of 92 [IP_ADDRESS]  Avoidance of Pregnancy  
Women of Child bearing Potential  
Pregnancy should be avoided by [CONTACT_826789] (see  Section  [IP_ADDRESS] ) for the duration of the study and a total period of 
[ADDRESS_1147043] be taken. These will include pregnancy testing 
at screening, at the s tart of each cycle , and follow -up.  
Female patient s who become pregnant during the study will be withdrawn.  
Women of Non-Childb earing Potential  
Female patients  of non -childbearing potential are defined as; no menses for [ADDRESS_1147044] 12 months, bilateral 
tubal occlusion/ligation and bilateral oophorectomy. A high follicle stimulating hormone 
(FSH) level in the post -menopausal range may be used to confirm a post -menopausal 
state in women not us ing hormonal contraception or hormonal replacement therapy. 
However, in the absence of 12 months of amenorrhea, a single FSH measurement is 
insufficient.  
[IP_ADDRESS]  Acceptable Forms of Contraception  
Highly effective methods of birth control are defined as those which result in a low 
failure rate (i.e. less than 1% per year) when used consistently and correctly.  
Acceptable forms of effective contraception are:  
• Combined oestrogen  and progestogen containing hormonal contraception (oral, 
intravaginal or transdermal) associated with inhibition of ovulation.  
• Progestogen -only hormonal contraception (oral, injectable, implantable) 
associated with inhibition of ovulation.  
• Intrauterine de vice.  
• Intrauterine hormone -releasing system.  
• Bilateral tubal occlusion.  
• Male sterilisation (with the appropriate post -vasectomy documentation of the 
absence of sperm in the ejaculate). For female patients  on the study, the 
vasectomised  male partner should be the sole partner for that patient .  
• True abstinence: When this is in line with the preferred and usual lifestyle of the 
patient . Periodic abstinence (e.g. calendar, ovulation, symptothermal, 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: [ADDRESS_1147045]-ovulation methods) and withdrawal are not acceptable meth ods of 
contraception.  
Acceptable birth control methods that result in a failure rate of more than 1% per year 
include:  
• Progesterone -only oral hormonal contraception, where inhibition of ovulation is 
not the primary mode of action  
• Barrier methods of contrac eption: condom or occlusive cap (diaphragm or 
cervical/vault caps) with spermicidal foam/gel/film/cream/suppository. The use of 
barrier contraceptives should always be supplemented with the use of a 
spermicide. The following should be noted:  
− Failure rates indicate that, when used alone, the diaphragm and condom are 
not highly effective forms of contraception. Therefore , the use of additional 
spermicides does confer additional theoretical contraceptive protection.  
− However, spermicides alone are inefficient at preventing pregnancy when 
the whole ejaculate is spi[INVESTIGATOR_54073]. Therefore, spermicides are not a barrier 
method of contraception and should not be used alone.  
[IP_ADDRESS]  Time Period for the Collection of Pregnancy Information  
All pregnancies in female patients  receiving  at least one dose of Cantrixil will be recorded 
from first dose to 3 months  after the final dose.  
[IP_ADDRESS]  Follow -up in the Event of a Pregnancy  
If a female patient becomes pregnant , the pregnancy will be recorded  and reported to the 
Sponsor within the same timeframe as SAEs (see Section 8.3.2 ). The Ethics Committee  
and the Sponsor will be informed. The patient will be asked  to provide information on the 
outcome of the pregnancy , including premature termination  should the case arise .  
Spontaneous miscarriage  and congenital abnormalities will be reported as S AEs.  
The follow -up period will be deemed to have ended when the health status of the child 
has been determined on his/her  birth.  
6.2.[ADDRESS_1147046] Withdrawals  
The Investigator  will make every reasonable attempt to ensure that all patients complete 
the study. A patient  may withdraw at any time for any reason. The Investigator  will 
advise the Sponsor of the withdrawal of any patient . 
A patient  may be withdrawn in any of the following circumstances:  
• Adverse event (s), 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 44 of 92 • Protocol violation , 
• Recurrence of an unacceptable AE or DLT despi[INVESTIGATOR_040] a Cantrixil dose level 
reduction , 
• Withdrawal of consent , 
• Termination of the study by [CONTACT_226112] ,  
• Completion of planned treatment and follow -up period . 
Patients who voluntarily withdraw are termed dropouts . 
Every effort will be made to complete all examinations scheduled on all patients who 
participate in the study, but do not complete the study according to the protocol. The 
Investigator  will make every effort to contact [CONTACT_391184] -up. 
Follow -up will continue for any patient with an ongoing AE at the time of study 
completion until the event resolves, or until the Sponsor and the Investigator  agree that 
further follow -up is not necessary.  
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: [ADDRESS_1147047](s)  
Cantrixil is manufactured as a clear solution for infusion (200 mg). One 10  mL glass vial 
(type I glass, siliconized ) with plunger stopper ( Westar® Flurotec stopp ers) contains 
10 mL of 20  mg/mL of the Active Pharmaceutical Ingredient (API) (TRX -E-002-1) in 
20% Dexolve -7. Before administration, Cantrixil concentrate solution for infusion is 
diluted in sodium chloride 9 mg/mL (0.9%).   
Stability studies are ongoing and the expi[INVESTIGATOR_826753]. After dilution, 
Cantrixil for infusion is stable for 24 hours at 2°C to 8°C. To prevent microbial 
contamination, the dilution should be used immediately after preparation. For more 
information on the formulation of Cantrixil, refer to the IB.  
7.1.[ADDRESS_1147048] be stored in the original packaging protected from light in a refrigerator 
(2°C to 8°C). Do not freeze. All Cantrixil  will be stored in the storage area of the study 
centre p harmacy, which is a secure, temperature controlled, locked  environment with 
restricted access.  
Cantrixil should only be prepared by a pharmacist or healthcare professional trained in 
the handling of cytotoxic drugs.  
7.1.[ADDRESS_1147049] 
be co mpleted and sent to the Sponsor.  
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: [ADDRESS_1147050] be used; ideally an aseptic suite  
will be used to prepare Cantrixil for administration. The outer surface of the vial is not 
sterile.  
• Based on the dose, the appropriate amount of air is extracted into a n appropriately 
sized syringe and needle.  
• An additional air buffer should be included i n the syringe.  
• The plastic lid from the Cantrixil pre -filled vial is removed.  
• The syringe needle is inserted through the rubber stopper of the vial being careful 
not to core the rubber stopper.  
• The appropriate volume of the vial (Cantrixil concentrate plus  air buffer) is 
extracted from the vial into the syringe; this process may need to be repeated if 
multiple vials are required to achieve the necessary volume of drug.  
• The syringe and needle is shaken gently to eliminate any air bubble(s) from the 
syringe.  
• Eject the entire contents of the syringe into a sterile bag of saline for infusion  to 
result in a total volume of 100 mL of fluid for infusion . Note that if a patient 
weighs more than 100kg then more than 100mL of undiluted Cantrixil would be 
required to d ose at 20mg/kg. Please contact [CONTACT_826790].  
• The plunger rod MUST NOT be drawn back to rinse the syringe, in order to avoid 
contamination and to ensure that the correct volume is ejected.  
• The peelable sticker, which is provided on the inner side of the Cantrixil carton 
box, displaying the text “Intraperitoneal use only.” must be attached to the saline 
infusion pack containing the diluted Cantrixil solution for intraperitoneal  infusion. 
This is a precautionary measure to ensure that Cantrix il is infused only via the 
intraperitoneal  route of administration.  
Method of administration  
Cantrixil must be administered via the intraperitoneal  route only ; an in -line filter must be 
part of the infusio n set . The Cantrixil solution should be warmed before administration. 
Once warm, the infusion bag should be hung and the drug allowed to infuse under gravity 
flow. Subsequent to each Cantrixil administration up to 1 L of warmed sodium chloride, 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 47 of 92 9 mg/mL (0. 9%) solution for injection shall be infused to support distribution of the 
Cantrixil solution in the abdominal cavity.  
Delivery of Cantrixil and combination chemotherapy  
All patients will have catheters/ports inserted to facilitate intraperitoneal  chemothe rapy 
administration. This intervention should be scheduled to occur as soon as possible after 
enrolment. All ports/catheters will be inserted by [CONTACT_826791]. Patients will be referred to the interventional 
radiologist or surgeon by [CONTACT_86297]. For intraperitoneal ports, the minimum 
period between port placement and the first administration of Cantrixil must not be 
shorter than 7 days. For other intraperitoneal access devices, th e period may be shorter if 
adequate stability and/or healing of the delivery system’s insertion site is confirmed by 
[CONTACT_1963].  
Insertion of the intraperitoneal port/catheter and intraperitoneal administration of 
Cantrixil and standard chemoth erapy will be done in accordance to each study centre’s 
Standard Operating Procedures and guidelines, or the recommended guidelines listed in 
Appendix B.  
The exact time that the intraperitoneal  infusion has completed must be recorded.  
Cycles [ADDRESS_1147051] chemotherapy agent  selected for the patient from Table 1 by [CONTACT_30780]/  Investigator . Standard therapi[INVESTIGATOR_826754] [ADDRESS_1147052] and 
study eCRFs. Before administration of the combination chemotherapy, the PK results for 
each patient from Part A/ Cycle 1 will be reviewed by [CONTACT_826792] e nsure that the PK 
profile of Cantrixil is indeed compatible with the proposed schedule for the  combination 
chemotherapy agent.  
With the anticipated PK profile of Cantrixil,  combination chemotherapy agents should  not 
be administered within 24 hours of Cantr ixil dosing to avoid any adverse drug -drug 
interactions.  
Cycles of Cantrixil  and the combined chemotherapy may continue until the patient fulfils 
any of the off-therapy  criteria, as described in Section 6.1. It is recommended that the 
catheter/port remain s in the abdominal cavity during the entire treatment period. If a 
catheter is used it is to be kept closed between infusions . 
7.3 Treatment Strate gy 
The clinical staff at the study centre are all responsible for the ongoing safety and 
well-being of the subjects while they are in the study centre.  
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: [ADDRESS_1147053]  be provided.  
7.5 Prior and Concomitant Medication  
In the interests of patien t safety and acceptable standards of medical care the Investigator  
will be permitted to prescribe supportive care treatment(s) at his/her discretion. Palliative 
radiotherapy is permitted on this study  but not within the peritoneum and also not during 
MTD cycle (Cycle 1). All treatments must be recorded in the patient s’ eCRF (medication, 
dose, treatment duration and indication).   
As TRX -E-002-1, the active ingredient of Cantrixil, may inhibit CYP450 drug 
metabolising enzym es, including CYP2C9, CYP2C8, CYP2C19, CYP2B6, CYP3A4, 
CYP2D6, CYP2A6 and CYP1A2, caution should be taken when administering drugs that 
are metabolised by [CONTACT_097]450 enzymes until further information is available. In particular, 
the potential interaction betwe en TRX -E-002-1 and paclitaxel, a CYP2C9 substrate 
frequently used in the treatment of ovarian cancer, needs to be considered.  As such the 
use of paclitaxel  is allowed, but only 24 hours after Cantrixil administration . 
 
7.6 Method of Assigning Subjects to Treat ment Groups  
At screening , potential study patient s will be assigned a screening number. The screening 
number will be prefixed with SCR. Following confirmation of eligibility, at study 
treatment  administration, patient s will be assigned a patient  number in the order in which 
they are enrolled in the study .  
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: [ADDRESS_1147054].  
Patient s who are replaced will be allocated the same treatment number prefixed with the 
number 1 e.g. if treatment number 009 is replaced then the replacement number will 
be 109. 
7.7 Randomis ation Procedures  (Not applicable)  
7.8 Maintenance of Randomi sation Codes  (Not applicable ) 
7.9 Blinding  (Not applicable ) 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 50 of 92 8 STUDY PROCEDURES  
Study assessments and procedures to be performed during the study are detailed in the 
Schedule of Assessments, Section 16; Table 4. All visits during treatment cycles [ADDRESS_1147055] a window of +/ - 1 calendar da y. During follow -up, the window is extended to +/ - 1 
week. The screening period is up to 28 days before the Cycle 1 Day 1 dose of Cantrixil.  
8.1 Pharmacokinetic Assessments  
Plasma Samples  
Pharmacokinetic studies will be performed on all patients. At each of the sampling 
periods a blood sa mple will be collected into a 4 mL dipotassium EDTA tube and the 
sample processed to plasma. The plasma samples will be divided into a primary and 
back-up sample and stored frozen at -80°C. The primary sample will subsequently be 
shipped to the bioanalytical laboratory. The results of the PK analysis will not be made 
available to the Principal Investigator,  Investigator s or any study centre  staff during the 
study. The  results will be made available to the DSMC/B for the purposes of patient 
safety . Blood sample collection times are included in the Schedule of Assessments  (see 
Section  16). 
Bioanalysis  
All bioanalytical procedures will be performed by [CONTACT_826793] ( The University of Queensland, 
Brisbane, Queensland, Australia),  according to their internal quality assurance protocols 
and procedures . Concentrations of TRX -E-002-1 in plasma will be determined using a 
validated liquid chromatography tandem mass spectrometry (LC -MS/MS) based assay . If 
one or more of the major active metabolites of TRX -E-002-[ADDRESS_1147056] 10% of the activity or toxicity observed, the PK of that/those metabolite(s) will also 
be measured . Full details of the bioanalytical analysis will be included separately in the 
Bioanalytical Report . 
8.2 Efficacy Assessments  
The following efficacy assessments will be measured ( sample collec tion times are 
included in the Schedule of Assessments  [see Section  16]): 
• PFS will be measured as the time from treatment starts until objective tumour 
progression as defined by [CONTACT_44993] 1.1 criteria  or GCIG criteria (see 
Appendix C) .  
• The time to pa racentesis will be measured as the time from treatment begin until 
the next paracentesis event.  
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 51 of 92 • The volume of paracentesis will be measured by [CONTACT_826794] . 
• Disease  response will be measured using RECIST  version 1.1 criteria ; the 
Gynecological Cancer Intergroup  (GCIG) response criteria  (described in Rustin et 
al., 2011) , which incorporates RECIST 1.1 and CA -125 measurements , may also 
be used to define disease response during Follow -up. Although the GCIG 
response criteria incorporating CA -125 measurements ha s been used successfully 
in clinical trials for recurrent ovarian cancer (Alexandre et al., 2012) , patients are 
not evaluable for CA -[ADDRESS_1147057] 28 days. Only the baseline and Follow -up 
measurements of CA -125, therefore, may be reliably used for determining 
response and progression  in this study . During Follow -up, the GCIG criteria, 
summarised in Appendi x C, may be used to define response and progression.  
• Concentration of CA -[ADDRESS_1147058] IP chemotherapy administration.  
The following exploratory endpoints  will also be assessed:  
• Enumeration of C ETC in peripher al blood and malignant ascites (if present) will 
be assayed using the MAINTRAC® CETC Count method by [CONTACT_826795] . This method uses a fluorochrome -labelled antibody against surface -
epi[INVESTIGATOR_779079] (EpCam) to tag C ETCs. Image analysis  allows C ETC numbers 
to be calculated in relation to blood volume over the course of treatment. Samples 
will be assayed at baseline, at the end of Cycle 2 and at the End of Therapy  for 
patients in Part A of the study only .  
• Clonogenicity of C ETCs in periph eral blood and malignant ascites (if present) 
will be measured using the MAINTRAC® Tumour Sphere Units assay by 
[CONTACT_826775] . Samples will be assayed at baseline, at the end 
of Cycle 2 and at the End of Therapy  for patients in Part A of the study only . 
• Expression of stem cell markers in the isolated colonies will be measured using 
labelled antibodies and scanning fluorescent microscopy techniques by [CONTACT_826796] . 
• Efficacy of twice w eekly doses o f Cantrixil as a monotherapy and combination 
therapy.  
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 52 of 92 These exploratory endpoints, if assessed, will be reported separately from the Clinical 
Study Report.  
8.3 Safety Assessments  
8.3.1  Adverse Events  
Definition s: 
Adverse Event  (AE) 
Any untoward medical occurrence i n a patient or clinical investigation subject 
administered a pharmaceutical product and which does not necessarily have to have a 
causal relationship with this treatment.  
An AE can therefore be any clinically significant sign (including an abnormal laborat ory 
finding, for example), symptom, or disease temporally associated with the use of a 
medicinal product, whether or not considered related to the medicinal product.  
Patients will be followed for [ADDRESS_1147059] ed as a participant outcome but not recorded on the 
adverse event log.  
Adverse Drug Reaction (ADR)  
Any untoward and unintended response in a patient  to an investigational medicinal 
product which is related to any dose administered to that patient . 
Serious Adverse Event (SAE)  
An adverse reaction is ‘serious’ if it:  
• Results in death;  
• Is life -threatening;  
• Requires hospi[INVESTIGATOR_359667] , excluding 
hospi[INVESTIGATOR_826755] ; 
• Results in persistent or significant disability or incapacity;  
• Consists of a congenital anomaly or birth defect;  
• Is a medically important event.  
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Lim ited 
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 53 of 92 Unexpecte d Adverse Reactions  
An adverse reaction is ‘unexpected’ if its nature and severity are not consistent with the 
information about the medicinal product in question set out:  
• In the case of a product with a marketing authorisation, in the summary of product 
characteristics for that product;  
• In the case of any other investigational medicinal product, in the IB relating to the 
trial in question . 
8.3.[ADDRESS_1147060] be fully recorded in the patient’s eCRF  from signing of informed 
consent until [ADDRESS_1147061] month of the 
follow -up period should only be recorded if the investigator deems them to be r elated to 
the investigational agent. Signs and symptoms of each AE should be described in detail: 
onset time and date, offset time and date, description of event, severity, relationship to 
investigational product, action taken and outcome.  The descriptions  and grading scales 
found in the revised NCI -CTCAE version 4.[ADDRESS_1147062] at follow -up. 
Reporting of SAEs and S[LOCATION_003]Rs  
SAEs occurring from the time of informed consent  will be reported to the S ponsor’s 
medical representative within 24 hours of the Investigator becoming aware of the event . 
The Investigator  will be requested to complete a separate SAE  reporting form in addition 
to the information in the eCRF . 
A suspected unexpected serious adverse reaction ( S[LOCATION_003]R ) which is fatal or 
life-threatenin g must be reported to the competent authority and Ethics Committee  
immediately  (within 7 days or according to local reporting requirements) ) after the 
Sponsor became aware of the event. Any additional information must be reported within 
eight days of sendi ng the first report.  
A S[LOCATION_003]R which is not fatal or life -threatening must be reported to the competent 
authority and Ethics Committee  as soon as possi ble (within 15 days  or according to local 
reporting requirements ) after the S ponsor bec omes aware of the e vent.  
8.3.3  Categorisation of Adverse Events  
Adverse event s will be graded according to the NCI -CTCAE version  4.03. Events which 
do not fit into any CTCAE category  will be categorised as follows:  
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 54 of 92 1 Mild:  Mild events are those which are easily tolerated with 
no disruption of normal daily activity.  
2 Moderate:  Moderate events are those which cause sufficient 
discomfort to interfere with daily activity.  
3 Severe:  Severe events are those which incapacitate and 
prevent usual activity.  
4 Life-threatening:  Life-threatening events have extremely serious 
consequences and urgent intervention is indicated  to 
avoid a fatal outcome . 
5 Death:  Death related to an AE  
8.3.4  Causa l Relationship Assessment  
The Principal  Investigator  [INVESTIGATOR_826756], and  answer ‘yes’ or ‘no’ to the question : ‘Do you consider that there is a 
reasonable possibility that the event may have been caused by [CONTACT_104841]?’ . For 
SAEs causal relationship will also be assessed for study treatm ent, other medication and 
study procedures.  
8.3.5  Action Taken  
Action taken will be defined as : 
• None ; 
• Dosing interrupted ; 
• Dosing stopped ; 
• Infusion delay . 
8.3.6  Outcome  
Outcome will be defined as:  
• Not recovered/not resolved ; 
• Recovered/resolved ; 
• Recovered/resolved with sequelae ; 
• Fatal ; 
• Unknown/lost to follow -up. 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 55 of 92 8.3.7  Coding of Adverse Events  
All AEs will be coded using the current version of Medical Dictionary for Regulatory 
Activities (MedDRA). A dverse event s will be categorised for  severity  according to the 
NCI-CTCAE Version  4.03. 
8.3.8  Pregnancy Reporting  
All pregnancies should be reported by [CONTACT_13658] 24  hours of notification on 
a Pregnancy Report Form.  
The outcome of all pregnancies (spontaneous miscarriage, elective termination, ectopic 
pregnancy, normal birth or congenital abnormality) sh ould be followed up and 
documented accordingly on the Pregnancy Report Form.  
Although pregnancy itself is not regarded as an AE, congenital abnormalities/birth defects 
and spontaneous miscarriages should be reported and handled as SAEs. Elective abortions 
without complications should not be handled as AEs.  
8.4 Clinical Laboratory Safety Tests  
Sample collection times are included in the Schedule of Assessments  (see Section 16). 
Clinical laboratory tests include haematology , serum chemistry and urinalysis and are 
listed below.  
Panel  Parameter  
Haematology  White blood cell count  Neutrophils absolute  
 Red blood cell count  Lymphocyctes absolute  
 Haemoglobin  Monocytes absolute  
 Haematocrit  Eosinophils absolute  
 Mean corpuscular volume  Basophils absolute  
 Mean corpuscular haemoglobin  Platelets  
 Mean corpuscular haemoglobin concentration   
Serum  Alkaline phosphatase  Sodium  
biochemistry  Alanine aminotransferase  Potassium  
 Creatine kinase  Urea  
 Gamma glutamyl transpeptidase  Creatinine  
 Lactate dehydrogenase  Albumin  
 Aspartate aminotransferase  Calcium  
 Total Bilirubin  Phosphate  
 Globulin  Glucose  
 Chloride  Magnesium  
Coagulation  Activated partial thromboplastin time  International normalised ratio  
Urinalysis  Leucocytes  Red blood cells  
(Dip-stick)  Protein  pH 
 Bilirubin  Nitrite  
 Urobilinogen  Specific gravity  
 Ketones  Glucose  
 Microscopy (if clinically indicated)   
Pregnancy test 
(serum)  Beta human chorionic gonadotropin   
 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 56 of 92 Additional and repeat testing may be performed at the discretion of the Investigator.  
Unless otherwise specified in the Laboratory Manual all clinical laboratory tests will be 
performed by [CONTACT_826797].    
8.5 Clinical Safety Assessments  
Assessment times are included in the Schedule of Assessments  (see Section 16). 
8.5.1  Physical Examination  
Physical examinations will be performed by a physician and will include the examination 
of the following: general appearance, head, eyes, ears, nose, throat, chest/ res pi[INVESTIGATOR_696], 
heart/ cardiovascular, gastrointestinal/ liver, musculoskeletal/ extremities, dermatological/ 
skin, thyroid/ neck, lymph nodes, neurological/ psychiatric. Complete physical 
examinations will be performed at screening and the final study  visit. Sy mptom -driven 
physical examinations will be performed where indicated at other specified time points, 
per the Schedule of Assessments ( Table 4). 
8.5.2  Vital Signs  
Systolic an d diastolic blood pressure (SBP, DBP), pulse rate, respi[INVESTIGATOR_826757] ( Table 4) after 
the subject has been in a supi[INVESTIGATOR_21683] [ADDRESS_1147063]’s arm unconstrained by [CONTACT_43979]. All measurements wi ll be 
obtained from the same arm and, using an automatic instrument with a digital readout, 
throughout the study. All readings must be recorded in the eCRF. Additional readings 
may be taken at the discretion of the Investigator . 
8.5.3  12-Lead Electrocardiogram ( ECG ) 
Computerised 12 -lead ECG recordings will be obtained according to the Schedule of 
Assessments ( Table 4). Each lead shall be recorded for at least 3 beats at a paper speed of 
25 mm/sec. Subjects will rest in a supi[INVESTIGATOR_21683] 5 minutes prior to 
recordings . Recordings will be obtained in triplicate.  
The following parameters will be recorded: rhyt hm, ventricular rate, PR interval, QRS 
duration and QT. The RR value will also be recorded so that the QTc F values can be 
calculated automatically by [INVESTIGATOR_14420].  
Where the ECG is recorded as abnormal, the abnormality will be specified.  
8.5.4  Medical History  
A comp lete medical history will include evaluation (past or present) of the following:  
general, head and neck, eyes, ears, nose throat, chest/ respi[INVESTIGATOR_696], heart/ cardiovascular, 
gastrointestinal/ liver, gynaecological/ urogenital, musculoskeletal/ extremities,  skin, 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 57 of 92 neurological/ psychiatric, endocrine/ metabolic, hematologic/ lymphatic, allergies/ drug 
sensitivities, past surgeries  and clinical outcomes , substance abuse or any other diseases 
or disorders . All prior cancer treatments and the clinical outcomes w ill also be recorded.  
8.[ADDRESS_1147064] (see Schedule of Assessments in Follow -up, 
Table 6). Patients withdrawing consent for the study, who have  study -related AEs, are 
encouraged to continue visits until  resolution or stabilisation of the AEs. Patients that are 
beginning on another treatm ent therapy before the end of the follow -up period must be 
formally withdrawn from this study. In this case, safety data should be collected until the 
day before the first study intervention on the new study.  
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 58 of 92 9  DATA COLLECTION  
A 21 CFR part 11 compliant Electronic Data Capture (EDC) system will be used for this 
study. Electronic CRFs will be utili sed. An eCRF is required to be completed for each 
subject  who provides informed consent . The completed eCRFs are the sole property of 
the Sponsor and s hould not be made available in any form to third parties, except for 
authorized representatives of the Sponsor or appropriate regulatory authorities, without 
written permission from the Sponsor. The Investigator has ultimate responsibility for the 
collecti on and reporting of all clinical, safety and laboratory data entered on the eCRFs 
and any other data collection forms (source documents) and ensuring that they are 
accurate, authentic/original, attributable, complete, consistent, legible, timely 
(contempor aneous), enduring and available when required. Any corrections to entries 
made in the source documents must be dated, initialled  and explained (if necessary) and 
should not obscure the original entry.  
In most cases, the source documents are the study centr e or the physician's subject chart  
or patient medical record . In these cases, data collected on the eCRFs must match the data 
in those charts  or medical records . All source documents will be retained by [CONTACT_826798].  
In some cases, the eCRF, or part o f the eCRF, may also serve as source documents. In 
these cases, a document should be available at the study centre as well as at the Sponsor 
clearly identify ing those data that will be recorded in the eCRF, and for which the eCRF 
will stand as the source d ocument  
Photocopi[INVESTIGATOR_826758] (i.e. for 
regulatory purposes) at the request of the Sponsor.  
The informed consent will be kept at the study centre with a copy of the completed source 
documents in the ap propriate Investigator site file folder provided, or a note to indicate 
where the records can be located. All records should be kept in conformance to applicable 
national laws and regulations.  
Validity and consistency of data will be checked by [CONTACT_826799] -programmed data 
validation rules that will be applied to the data extracted from the EDC system during the 
course of the study. The data management team will raise queries in the EDC system to 
resolve discrepancies. The Investigator must verify that all data entries in the eCRFs are 
accurate and correct. After completion of the study and when all collected data is 
validated, the database will be locked, pursuant to the prior approval by [CONTACT_941] S ponsor. 
Final data will be extracted from the EDC and delivered to the Sponsor in the form of 
SAS® datasets. A PDF copy of the eCRF will be produced for each study subject and 
included in the final delivery.  
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: [ADDRESS_1147065] be  documented and a log of all EDC users and their 
rights within the system be maintained.  
Adverse events will be coded using the current MedDRA thesaurus; concomitant 
medication will be coded using the World Health Organisation (WHO) Drug Dictionary 
(DD) (i f required).  
The EDC system will keep track of all data entries, alterations and query resolution in an 
audit trail. The audit trail will form an integral part of the database and will be archived 
alongside the data.  
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 60 of 92 10  EVALUATION OF STUDY DATA  
10.1  Evaluation of Pharmacokinetic Parameters  
Summary statistics will be presented for Cantrixil ( TRX -E-002-1) plasma concentrations 
at each scheduled time point by [CONTACT_42376] (for example, mean, geometric mean, 
median, standard deviation [SD], standard error of the mean  [SEM], coefficient of 
variation [CV] and range). Summary statistics will also be presented by [CONTACT_826800], including  
• Area under the plasma concentration -time curve from time zero to the last 
quantifiable concentration (AUC 0-last), 
• Maximum plasma concentration (C max) and  
• Time to maximum plasma concentration (t max), plus if estimable:  
• Area under the plasma concentration -time curve from time zero extrapolated to 
infinity (AUC 0-∞), 
• Apparent terminal half -life (t 1/2), 
• Clearance (CL) and  
• Volume of distribution (Vd) .  
All concentrations below the limit of quantification and/or missing data will be labelled 
as such in the concentration data listings. Concentrations below the limit of quantification 
which are after C max will be treated as missing in summary statistics and for the 
calculation of pharmacokinetic parameters. Pharmacokinetic parameters will be 
determined by [CONTACT_364397] -compartmental pharmacokinetic analyses using Phoenix  64 
WinNonLin software.  
The PK assessmen t results will be described in a PK study report prepared by [CONTACT_826801].  
10.2  Evaluation of Pharmacodynamic/Efficacy Measures  
Not applicable.  
10.3  Evaluation of Safety  
The safety evaluation will include vital signs , ECG parameters, clinical laboratory tests 
(haematology, serum biochemistry, coagulation, urinalysis and urine microscopy  [if 
clinically indicated] ) and AEs. 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 61 of 92 11  STATISTICAL METHODS  
The default summary statistics for continuous variables include number of contributing 
observations (n), mean, SD, median, minimum and maximum.   
For categorical variables, the number (n) and percentage (%) (the percentage of subjects 
in each category relative to the total number of subjects in the relevant analysis 
population or relative to the total num ber of subjects in the relevant analysis population, 
with assessments available [where appropriate]) in each category will be the default 
summary presentation.  
Unless otherwise specified, “Baseline” is defined as the last observed value of the 
parameter o f interest prior to the first intake of study medication (this includes 
unscheduled visits). For numerical variables, change from Baseline will be calculated as 
the difference between the value of interest and the corresponding baseline value.  
Unless other wise specified, all statistical estimate s will be provided at the 5% 
significance level. In case of normality assumption violation , an  appropriate 
non-parametric method will be used for analysis, where applicable.  
All data will be presented in by-subject listings.  
The statistical analysis will be performed using SAS® Version 9.2 or higher.  
All details regarding the statistical analysis and the preparation of tables, listings and 
figures will be described in the Statistical Analysis Plan (SAP) prepared by [CONTACT_826802] . 
11.[ADDRESS_1147066] 
chemotherapy, an appropriate sample size is not statistically determined.  
The dose -escalation Cyc le 1/Part A of the study is designed to determine the MTD of 
Cantrixil as a monotherapy in patients with ovarian cancer , Fallopi[INVESTIGATOR_826759] . The planned dose levels include 0.24, 0.6, 1.25, 2.5, 5, 10  and, 
20 mg/kg. From ini tial dose level, single patient cohorts will be used until an AE is 
observed during Part A/Cycle 1 that meets the definition of a DLT or warrants further 
examination in the opi[INVESTIGATOR_826760]/B (see Section 
6.1) and then the dose escalation will follow the 3+[ADDRESS_1147067] chemotherapy through Cycles 3 to 8 in Part A of the study. Patients who don’t 
experience a DLT but who do not complete Cycle 1 of therapy will be replaced. To 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 62 of 92 establi sh MTD in Part  A/Cycle 1  of the study, up to 42 patients will be enrolled. An 
expanded cohort with 12  patients will be enrolled and treated at MTD in Part B of the 
study.  
The total sample size may be up to 54 patients (up to 42 in Part A, 12 in Part B) enrolled 
into this study.   
11.[ADDRESS_1147068] Population s for Analyses  
Maximum Tolerated Dose (MTD) population :  
The MTD population will include all patients who experienced DLTs in Cycle 1 /Part A, 
and those who received all three weekly doses of study treatment in Cycle 1/Part A. The 
safety data regarding the Cycle 1/Part A will be used to determine MTD from this 
analysis population.  
Safety (SAF) population :  
The SAF population will include all enrolled patients who recei ve at least 1 dose of study 
treatment . All safety analyses will be conducted on this population.  
Pharmacokinetic (PK) population :  
The PK population will include all SAF patients who with at least 1 PK assessment. All 
PK analyses will be conducted on this  population.   
Intent -to-Treat (ITT) population :  
The ITT population will include all enrolled patients who receive at least [ADDRESS_1147069] -baseline efficacy measurement is obtained. All 
efficacy analyses will be co nducted on this population and will be based on the actual 
dose level/single -weekly or twice weekly doses of Cantrixil at which each patient has 
been treated.  
The number and percentage of the patients included in the analysis populations will be 
reported i n a table showing the reason of exclusion for all patients enrolled into study. A 
listing of reasons of exclusion from analysis population will be provided. Patients who 
were screened but never started a dose will be listed. Screening failures will not be 
included in any of the summary tables.  
11.3  Pharmacokinetic Analysis  
Summary statistics will also be presented by [CONTACT_826803] 10.1.  
The PK assessment results will be described in a PK study report prepared by [CONTACT_826801].  
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: [ADDRESS_1147070] version 1.1 criteria ; disease response 
may also be assessed using the Gynecological Cancer Intergroup (GCIG) response 
criteria that incorporates CA -125 measurements during Follow -up (see Appendix C) . 
Assessment of target lesions response (Complete Response; Partial Response; Progressive 
Disease; Stable Disease) , non-target lesions response (Complete Response; Stable 
Disease; Partial Response)  and CA -[ADDRESS_1147071] 1.1 and CA -125 criteria.  
The Kaplan -Meier survival curves and 25th, 50th (median), and 75th percentiles will be 
provided along with their 2 -sided 95% confidence intervals (CIs) for PFS.  
The time to para centesis data will also be summarised as another time -to-event endpoint.  
The volume of abdominal fluid will be summarised using descriptive statistics by [CONTACT_167623].  
11.5  Exploratory Analysis  
Enumeration and Clonogenicity of C ETC in peripheral blood and malignant ascites will 
be performed at baseline, at the end of Cycle 2 and at the End of Therapy . Continuous  
response data (C ETC numeration ) will be summarised for each dose cohort. For 
continuous data like CETCs, number of c olonies  and number of c olonies  positive per mL 
of blood and/or per CETC for a stem cell marker , descriptive statistics will be provided.  
More details on analysis method or data presentation will  be described in the SAP.  
11.6  Safety Data Analysis  
Demographic and baseline disease characteristics data including age, gender, height, 
weight, tumour type, medical condition, etc. will be listed individually by [CONTACT_826804] c ohort using descriptive statistics (number of 
observations, median, minimum, maximum, mean and SD). Categorical variables 
(gender, ethnicity and race) will be summarised using frequencies and percentage. The 
SAF population will be used.  
Maximum tolerated d ose 
For determination of the MTD, individual subject data from the dose escalation part  
(Cycle  1/Part A) will be reported. In addition, for the final statistical analysis, the 
following will be analysed:  
• At each dose level, the number and proportion of sub jects in the DLT population 
who experience a DLT during the first DLT evaluation period  (Cycle 1/Part A) . 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therap eutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 64 of 92 • At each dose level, the number and proportion of treatment emergent AEs 
(TEAEs) experienced by [CONTACT_826805]  (Cycle 1/Part A) . 
The MTD will be determined according to the dose -escalation plan described in 
Section  6.1.2  (Table 3).  
The MTD is defined as the highest dose level at which no more than [ADDRESS_1147072] out of 
6 subjects treated in a cohort and evaluable for DLT determination experiences a DLT.  
Safety and tolerability  
Safety analyses will be performed on the SAF population.  
Adverse events will be coded using MedDRA and will be summarised by [CONTACT_12360] ( SOC ), Preferred Term, and dose cohort. Severity of AEs will be graded using the 
CTCAE v ersion 4.[ADDRESS_1147073] chemotherapy medications will 
be separately summarised  by [CONTACT_42376]. Safety laboratory tests and vital signs 
assessments, will be summarised by [CONTACT_826806], as appropriate.   
Dose limiting toxicities, safety and tolerability data will also be separately su mmarised 
for Cycle s 1 and 2,  and Cycle s 3 to 8 at MTD from Part A and Part B study, as 
appropriate. A detailed SAP will be finalised prior to clinical database lock of the study.  
Concomitant Medications  
All medications will be coded using the WHO -DD and An atomical Therapeutic Chemical 
(ATC) system. Each medication will be classified as prior medication if it is stopped prior 
to the first dose of Cantrixil , or as concomitant medication if it is on -going at the time of 
the first dose or is started after the f irst dose of Cantrixil . Prior and concomitant 
medications will be summari sed by [CONTACT_826807] [ADDRESS_1147074] will be classified into low/normal/high group by [CONTACT_826808]. 
For each laboratory test (e.g. haematology, biochemistry) a listing of laboratory values 
will be provided by [CONTACT_90715], patient and dose cohort. The frequency of 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 65 of 92 notable lab abnormalities (i.e. newly occurring CTCAE Grade 3 or Grade  4 laboratory 
toxicities), will be displayed by [CONTACT_46642], cycle, and dose cohort. A separate listing will 
display notable laboratory abnormalities (i.e., newly occurring CTCAE Grade 3 or 
Grade  4 laboratory toxicities).  
Laboratory data will be summari sed by [CONTACT_826809] 4.03 allows classification. All remaining data will be 
summari sed by [CONTACT_540882]. Laboratory data will also 
be displayed by [CONTACT_826810] (means, medians, standard deviations, ranges).  
Vital Signs  
Vital signs results will be presented using descriptive statistics of raw data and change 
from baseline values (means, medians, standard deviations, ranges).  
Physical Examinations  
Physical examination results will be summarised using frequency tables for 
normal/abnormal results per visits.  
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 66 of 92 12  STUDY REPORT  
A clinical study report , compliant with the requirements of ICH E3 , will be prepared by 
[CONTACT_163571] .  
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 67 of 92 13  REGULATORY AND ETHICAL ISSUES  
13.1  Regulatory and Ethics Review and Approval  
This study is to be conducted according to globally accepted standards of GCP (as 
defined in the ICH E6 Guideline for GCP), in agreement with the latest revision of the 
Declaration of Helsinki and in keepi[INVESTIGATOR_254797]. Before initiation of the 
study, approvals from the applicable Regulatory Authority(ies) will be obtained  where 
relevant . The Investigator  must obtain approval or favourable opi[INVESTIGATOR_29925] , 
Informed Consent Form (ICF) and any adv ertisement for patient recruitment from the 
Ethics Committee  complying with the applicable pertinent government regulations. The 
Ethics Committee  will evaluate the ethical, scientific and medical appropriateness of the 
study.  
The documents submitted will i nclude but are not limited to;  
• The final protocol , 
• The IB , 
• The ethics application form , 
• The ICF . 
The study will not commence unless the following conditions are satisfied:  
• The IRB has given a favourable opi[INVESTIGATOR_826761]; and  
• The study has b een authorised by [CONTACT_826811] . 
13.[ADDRESS_1147075] been answered and the Investigator  
is assured that the individual understands the implications of participating in the study, 
the patient will be asked to give consent to participate in the s tudy by [CONTACT_826812]. The Investigator  will provide a copy of the signed and dated 
ICF to each patient.  
The nature of the ICF will comply with the current version of the Declaration of Helsinki, 
the current requirements of GCP and  local regulations, which ever provides the greater 
patient protection.  
If an amendment to the Clinical Study Protocol (CSP) changes the patient participation 
schedule in scope or activity, or increases the potential risk to the patient, the ICF must be 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: [ADDRESS_1147076] be used to obtain consent from any patient currently enrolled in the study if 
he/she is affected by [CONTACT_29991]. The revised ICF must be used to obtain consen t 
from any new patients who are enrolled into the study after the date of the approval or 
favourable opi[INVESTIGATOR_826762].  
The signed and dated declaration of informed consent will remain at the Investigator ’s 
study centre, and must be safely ar chived by [CONTACT_826813], auditing, and inspection purposes .  
13.[ADDRESS_1147077] to compen sation payable to the patient. The amount of compensation will be 
calculated by [CONTACT_826814].  
The Investigator s declare to having insurance cover for  the malpractice and/or negligence 
of their employees and agents.  
 
 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 69 of 92 14  STUDY MANAGEMENT  
14.1  Quality Assurance and Quality Control  
In accordance with the guideline for ICH  GCP, the S ponsor has responsibility for 
implementing and maintaining quality assurance and quality control systems, and the 
ultimate responsibility for the quality integrity of the trial data resides with the Sponsor.  
Data will be captured in a standardised format a ccording to the study centre’s standard 
operating procedures and those procedures specified in the study documentation.  
A [ADDRESS_1147078] patient : 
• Regulatory authorisation ; 
• Copy of current Investigator ’s Brochure ; 
• Risk assessment report ; 
• Completed and signed Investigator  agreement/contract ; 
• Signed original of the final protocol ; 
• Ethics Committee approval ; 
• Copy of the constitution of the Rese arch Ethics Committee ;   
• A list of members of the Ethics Committee ; 
• A copy of the consent form and patient  information to be used ; 
• The curriculum vitae of all Investigator s; 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 70 of 92 • A clinical trial agreement between the S ponsor and the study centre  defining  the 
responsibilities of the Sponsor, the study centre  and any third parties significantly 
involved in the supply chain of the IMP, where applicable ; 
• A list of laboratory reference range values for parameters measured in the study . 
14.[ADDRESS_1147079] access to the source data/documents.  
14.[ADDRESS_1147080] between the parties and the prevailing safety and well -being of patients.  
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: [ADDRESS_1147081] 15 years after the conclusion of the study and that during that period 
are: 
• Readily available to the licensing authority on request; and  
• Complete and legible.  
All data derived from the study will remain the property of Kazia Therapeutics Limited . 
The study will be the subject of a final CSR co mpi[INVESTIGATOR_77251], or by [CONTACT_826815]  [INVESTIGATOR_826763] E3.  
All correspondence (e.g. with the Sponsor, Ethics Committee ) relating to this study 
should be kept in the appropriate file folder s. 
Records of patient s’ source documents, eCRF’s, IMP inventory, pertaining to the study 
must be kept on file. Records must be retained according to the current ICH Guidelines 
on GCP.  
The records should be retained by [CONTACT_826816], local regulations, or as 
specified in the Clinical Study Agreement, whichever dictates a longer period. The 
Sponsor shall appo int named individuals within their  organisation to be responsible for 
archiv ing the documents which are, or have been, contained in the Trial Master File. 
Access to those documents shall be restricted to those appointed individuals. If there is 
transfer of ownership of data or documents connected with the clinical study:  
• The Spons or shall record the transfer; and  
• The new owner shall be responsible for data retention and archiving.  
If the Investigator  moves, withdraws from an investigation or retires, the responsibility 
for maintaining the records may be transferred to another perso n who will accept 
responsibility. Notice of transfer must be made to and agreed by [CONTACT_1034] . 
14.[ADDRESS_1147082] undertake not to sub mit any part of the individual data 
from this protocol for publication without prior consent of the Sponsor at a mutually 
agreed time.  
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 72 of 92 15  REFERENCES  
 
Alexandre, J., C. Brown, D. Coeffic, N. Raban, J. Pfisterer, J. Maenpaa, H. Chalchal, B. 
Fitzharris, B. Vol gger, I. Vergote, C. Pi[INVESTIGATOR_1336], A. Ferrero and E. Pujade -Lauraine (2012). 
CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience 
of the GCIG CALYPSO trial. Br J Cancer 106(4): [ADDRESS_1147083] H. 
A., Moreno  O., Esquibel  V., Levin  W. and Moore  K. N. (2014). Phase 1, open -label, dose 
escalation, safety, and pharmacokinetics study of ME -344 as a single agent in patients 
with refractory solid tumo rs. Cancer. 121(7):1056 -63. 
 
Brown D. M., Heaton  A. and Husband A. J. (2008). Idronoxil. Drugs of the Future . 
33(10): 844-860. 
 
Cantrixil Investigator ’s Brochure, (2016) Version 1.0, July 2016, Kazia Therapeutics 
Limited . 
 
Dizon, D., W. Brady, H. E. Lankes, D. A. Jandial, S. B. Howell, R. J. Schilder, J. H. 
Beumer, S. M. Christner, S. Strychor, M. A. Powell, A. R. Hagemann, K. N. Moore, J. L. 
Walker, P. DiSilvestro and P. M. Fracasso (2015). Results of a phase I pharmacokinetic 
study of intraperitonea l bortezomib (B) and carboplatin (C) in patients with persistent or 
recurrent ovarian cancer (OC): An NRG/Gynecologic Oncology Group study. J Clin 
Oncol  33 (suppl; abstr 5515)  
 
 
Gordon, A. N., M. Tonda, S. Sun and W. Rackoff (2004). Long -term survival adv antage 
for women treated with pegylated liposomal doxorubicin compared with topotecan in a 
phase 3 randomized study of recurrent and refractory epi[INVESTIGATOR_76296]. 
Gynecologic Oncology  95(1): 1 -8. 
 
Gourley C., Walker J.L. and Mackay H.J. (2016). Upd ate on Intraperitoneal 
Chemotherapy for the Treatment of Epi[INVESTIGATOR_115345] . American Society of 
Clinical Oncology educational book. 35:143 -51. 
 
FDA Guidance 2005 , U.S. Department of Health and Human Services , Food and Drug 
Administration , Center fo r Drug Evaluation and Research (CDER ) (2005) Guidance for 
Industry: Estimating the Maximum Safe  Starting Dose in Initial Clinical  Trials  for 
Therapeutics in Adult Healthy  Volunteers .  
 
Fotopoulou C., Vergote I., Mainwaring P., Bidzinski M., Vermorken J. B. , Ghamande S. 
A., Harnett P., Prete S., Del A., Green J. A., Spaczynski M., Blagden S., Gore M., 
Ledermann J., Kaye S. and Gabra H. (2014). Weekly AUC2 carboplatin in acquired 
platinum resistant ovarian cancer with or without oral phenoxodiol, a sensitizer  of 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 73 of 92 platinum cytotoxicity: the phase I II OVATURE multicenter randomized study, A nnals of 
Oncology.  25:160 -65. 
Jaaback, K., Johnson N. and Lawrie T. A. (2011). Intraperitoneal chemotherapy for the 
initial management of primary epi[INVESTIGATOR_76296], Cochrane Database of 
Systematic Reviews: CD005340.  
 
Le Tourneau C., Lee J. J., and Siu L.L. (2009). Dose Escalation Methods in Phase I 
Cancer Clinical Trials, Journal of the National Cancer Institute, 101:708 -20. 
 
Markman, M., J. Blessing, S. C. Ru bin, J. Connor, P. Hanjani and S. Waggoner (2006). 
Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel -resistant ovarian 
and primary peritoneal cancers: A Gynecologic Oncology Group study. Gynecologic 
Oncology 101(3): 436 -440. 
 
Markma n, M., K. Webster, K. Zanotti, B. Kulp, G. Peterson and J. Belinson (2003). 
"Phase 2 trial of single -agent gemcitabine in platinum -paclitaxel refractory ovarian 
cancer." Gynecologic Oncology 90(3): [ADDRESS_1147084], K. Moore, J. C. Ben dell, C. Kurkjian, S. F. Jones, O. Moreno, 
J. G. Kuhn, S. McMeekin and J. R. Infante (2014). A first -in-human dose -escalation study 
of ME -143, a second generation NADH oxidase inhibitor, in patients with advanced solid 
tumors. Invest igational  New Drugs 32( 1):[ADDRESS_1147085] and D. H. 
Moore (2003). A phase II study of docetaxel in paclitaxel -resistant ovarian and peritoneal 
carcinoma: a gynecologic oncology group study. Gynecologic Oncology 8 8(2): 130 -135 
 
 
Rustin, G. J., I. Vergote, E. Eisenhauer, E. Pujade -Lauraine, M. Quinn, T. Thigpen, A. du 
Bois, G. Kristensen, A. Jakobsen, S. Sagae, K. Greven, M. Parmar, M. Friedlander, A. 
Cervantes, J. Vermorken and I. Gynecological Cancer (2011). Defin itions for response 
and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA-125 
agreed by [CONTACT_74363] (GCIG). Int J Gynecol Cancer 21(2): 
419-423. 
 
Saif, M. W., E. Tytler, F. Lansigan, D. M. Brown and A. J. Husband (2009). Flavonoids, 
phenoxodiol, and a novel agent, triphendiol, for the treatment of pancreaticobiliary 
cancers. Expert Opin ions on  Investig ational  Drugs 18(4):469 -479. 
 
Sehouli, J., D. Stengel, P. Harter, et al. (2011). Topotecan Weekly Versus  Conventional 
5-Day Schedule in Patients With Platinum -Resistant Ovarian Cancer: a randomized 
multicenter phase II trial of the North -Eastern German Society of Gynecological 
Oncology Ovarian Cancer Study Group. J Clin Oncol 29(2):242 -248. 
 
Senderowicz A. M . (2010). Information Needed to Conduct First -in-Human Oncology 
Trials in the [LOCATION_002]: A View from a Former FDA Medical Reviewer, Clinical 
Cancer Research, 16:1719 -25. 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 74 of 92  
Tewari D ., Java J. J., Salani  R., Armstrong  D.K.,  Markman  M., Herzog  T., Monk  B.J. and 
Chan  J.K. (2015 ). Long -Term Survival Advantage and Prognostic Factors Associated 
With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A 
Gynecologic Oncology Group Study . Journal of Clinical Oncology, 33:1460 -66. 
 
Trimble E. L., and Alvarez  R. D.  (2006 ). Intraperitoneal chemotherapy and the NCI 
clinical announcement, Gynecol ogic Oncol ogy, 103:S18 -9. 
 
Walker, J. L. (2013 ). Intraperitoneal chemotherapy requires expertise and  should be the 
standard of care for optimally surgically resected epi[INVESTIGATOR_388042] . 
Annals of Oncol ogy, [ADDRESS_1147086] 10:x41 -45. 
 
Wang, X., R. McKernan, K. H. Kim, A. B. Alvero, A. Whiting, J. A. Thompson, G. Mor, 
M. W. Saif, A. J. Husband, D.  M. Brown and E. M. Tytler (2011). Triphendiol (NV -196), 
development of a novel therapy for pancreatic cancer. Anticancer Drugs 22(8):719 -731. 
 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 
 Page 75 of 92 16  STUDY SCHEDULE  
The procedures and assessments to be performed during each part of the study are 
outlined in th e Schedule of Assessment ( Table 4), the Schedule of PK Assessments 
(Table 5) and the Schedule and Assessments in Follow -up (Table 6).  
Actual Cantrixil and chemotherapy administ rations and the date and time of study 
assessments will be recorded in the patient’s eCRF. If any abnormalities in safety 
assessments are observed, repeat measurements may be performed at the discretion of the 
Investigator.  
  
CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 Page 76 of 92 Table 4 Schedule of Assessments  
  
Screening# Part A and B: Cycle 1  Part A and B: Cycles 2 to 8  
Continued 
Access   
dOff 
Therapy/ 
End of 
Therapy  
Week 1  Week 2  Week 3  Week 1  Week 2  Week 3  Weeks 
1,2,3   
Cantrixil Administration   Day 1  
(+/- 1 day)  Day 8  
(+/- 1 day)  Day 15  
(+/- 1 day)  Day 1  
(+/- 1 day)  Day 8  
(+/- 1 day)  Day 15  
(+/- 1 day)  Days 
1,8,15  
(+/- 1 day)   
Informed consent  X         
Catheter/port placement  Xa         
Demographics  X         
Medical history, including number, type 
of prior therapi[INVESTIGATOR_014], start and stop dates  X         
Prior and concomitant medication  Xa Xa X X X X X  X 
Physical examination  Xa Xa X X X X X As per 
Standard 
of Care  X 
Vital signs  Xa Xa X X X X X X 
Height  X        
Weight  Xa Xa   X    
Pregnancy testing  X X   X   X 
ECOG Performance Status  Xa Xa X X X X X X 
Safety Laboratory assessmentsf Xa Xa X X X X X X 
CA-125 Testing  X X X X X X X X 
Urine – dip stick  Xa Xa X X X X X X 
Triplicate 12 -Lead electrocardiogram  X X   X    
AE evaluation   X X X X X X X X 
Radiologic evaluation  Xb      Xb As per 
SOC  Xb 
Tumour measurements  Xb      Xb Xb 
Pharmacokinetic studies   Xc   Xc Xc    
 Part A 
Screening# Part A : Cycle 1  Part A: Cycles 2 to 8    
Biomarker Samples  – Part A only  Xe    Xe    Xe 
AE: Adverse event; CT: Computed Tomography; ECOG: Easte rn Cooperative Cancer Group; MRI: Magnetic Resonance Imaging; PI: [INVESTIGATOR_678] ;  
CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 Page 77 of 92 # The screening period is up to 28 days before the Cycle 1 Day 1 dose of Cantrixil.  
a These assessments may coincide, for example if patient already has a port then  the pre -study/eligibility assessments may occur on the same day as the first day of 
Cantrixil administration. Otherwise, it is anticipated that there will be a delay between the pre -study/eligibility assessments and the first day of therapy to allow for 
the placement of the port/catheter.  
b Radiologic evaluations and subsequent tumour measurements should be conducted at the end of each six -week period, coinciding with the end of each two cycles of 
therapy. The subsequent cycle of therapy should not proceed  until this assessment has been evaluated because clear tumour progression may preclude further 
treatment on this study. The PI [INVESTIGATOR_826764] (either MRI or CT) but the same modality must be u sed for all time -points . 
c Pharmacokinetic samples are collected in these weeks per the schedule described in Table 5. 
d The “ End of Therapy/ Off Therapy” assessments may coincide with the assessments performed at one of the other designated time -points.  
e  Biomarker samples are  collected at screening, end of Cycle 2 (most conveniently collected on Day 1  of Cycle 3 before IP administration) and End of Therapy , 
during Part A  of the study only . 
f Safety assessments as per Section 8.[ADDRESS_1147087] Parameter  
Haematology  White blood cell count  Neutrophils absolute  
 Red blood cell count  Lymphocyctes absolute  
 Haemoglobin  Monocytes absolute  
 Haematocrit  Eosinophils absolute  
 Mean corpuscular volume  Basophils absolute  
 Mean corpuscular haemoglobin  Platelets  
 Mean corpuscular haemoglobin concentration   
Serum  Alkaline phosphatase  Sodium  
biochemistry  Alanine aminotransferase  Potassium  
 Creatine kinase  Urea  
 Gamma glutamyl transpeptidase  Creatinine  
 Lactate dehydrogenase  Albumin  
 Aspartate aminotransferase  Calcium  
 Total Bilirubin  Phosphate  
 Globulin  Glucose  
 Chloride  Magnesium  
Coagulation  Activated partial thromboplastin time  International normalised ratio  
 
CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 Page 78 of 92 Table 5 Proposed PK Schedule  (Part A and Part B)  
PK 
Time 
Point  Cycle:Day:Hour:Minutea Rationale  
T1 Cycle 1  D1 00:00 ( pre-dose) Baseline before Cycle 1  
T2 Cycle 1  D1 00:05 (end of 
infusion)  Samples to measure tmax and t1/[ADDRESS_1147088] 
monotherapy dose/ first exposure  
T3 Cycle 1  D1 00:[ADDRESS_1147089] -dose 
T4 Cycle 1  D1 01:00  
T5 Cycle 1  D1 02:00  
T6 Cycle 1  D1 04:00  
T7 Cycle 1  D1 06:00  
T8 Cycle 1  D2 24:00  
Process, freeze and batch above samples; ship for analysis on D3 of Cycle 1 (or following 
Monday to avoid weekend arrival at TetraQ)  
T9 Cycle 3 D1 00:00 ( pre-dose) Check no accumulation after Cycle s 1 and 2 
T10 Cycle 3  D1 00:05 (end of 
infusion)  To facilitate the interpretation of any 
differences seen between Cycle 1/D1 and 
Cycle 3/D8. Without data from Cycle 3/D1, 
we won’t be able to conclude whether 
differences between Cycle 1/D1 and 
Cycle  3/D8 are attributable to repeated 
dosing with Cantrixil or an interaction with 
the combination chemotherapy.  T11 Cycle 3  D1 00:30  
T12 Cycle 3  D1 01:00  
T13 Cycle 3  D1 02:00  
T14 Cycle 3  D1 04:00  
T15 Cycle 3  D1 06:00  
T16 Cycle 3  D2 24:00+ (before  
comb ination  chemo therapy  
administration)  Check efficient elimination of Cantrixil 
before administration of combination 
chemotherapy to avoid any drug -drug 
interactions.  
T17 Cycle 3 D8 00:00 ( pre-dose) Baseline  Before  Comb ination  Chemotherapy  
Dose  
T18 Cycle 3  D8 00:05 (end of 
infusion)  Samples to measure tmax and t1/[ADDRESS_1147090] 
combination therapy dose/ check whether 
combination therapi[INVESTIGATOR_826765]  
 
 T19 Cycle 3  D8 00:30  
T20 Cycle 3  D8 01:00  
T21 Cycle 3  D8 02:00  
T22 Cycle 3  D8 04:00  
T23 Cycle 3  D8 06:00  
T24 Cycle 3  D9 24:00  
Process, freeze and batch above samples; ship for analysis on D10 of Cycle 3 (or following 
Monday to avoid weekend arrival at TetraQ)  
PK: Pharmacokinetics  
a A 15 -minute window will be allowed for samples taken pre -dose; a [ADDRESS_1147091] -dose; a 15 -minute window for samples 
taken 2  to 6 hours’  post-dose and a 2 -hour window for samples taken 24 hours’  post-dose.  
 
 
 
 
 
CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 Page 79 of 92  
Table 6 Schedule of Assessments in Follow -up 
 4* weeks  
follow -up 8* weeks  
follow -up 12* weeks  
follow -up 
Concurrent meds  X X X 
Physical exam  X X X 
Vital signs  X X X 
Weight  X X X 
Performance Status  X X X 
Safety Laboratory 
Assessments  X X X 
CA-125 testing  X X X 
ECG (if indicated)     
AE evaluation  X   
Radiologic evaluationb  Xb X 
Tumour measurements   X X 
*  ±1 week is acceptable  
AE: Adverse event; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BUN: Blood Urea 
Nitrogen; CBC: complete blood count; CT: Computed Tomography; ECG: electrocardiogram;  LDH: 
Lactate dehydrogenase; LFT: liver function test ; MRI: Magnetic Resonance Imaging, SGO T: Serum 
glutamic oxaloacetic transaminase, SGPT: Serum glutamic pyruvate transaminase  
a CBC with differentials and platelets, a lbumin, alkaline phosphatase, total bilirubin, bicarbonate, 
BUN, calcium, chloride, creatinine, glucose, LDH, magnesium, phosphorus, potassium, total 
protein, SGOT[AST], SGPT[ALT], sodium. Include serum urea nitrogen; serum creatinine.  
b The P rincipal Investigator  can use the imaging modality of preference (either MRI or CT) but the 
same modality must be used for all time -points ; the tumour measurement can be done between 6 
and 8 weeks.  
 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 Page 80 of 92 17 PROTOCOL SIGNATURES  
INVESTIGATOR  SIGNATURE:  
 
I agree with the content of this protocol and the confidential nature of the documentation 
made as part of this stud y. I also acknowledge that the S ponsor of the study has the right 
to discontinue the study at any time. I have read the protocol and understand it and will 
work according to it and according  to the principles of Good Clinical Practices, applicable 
laws and regulations, and the Declaration of Helsinki.  
 
 
 
   
Principal Investigator   [CONTACT_1782]  
<Insert name [CONTACT_263335]>   
<Insert name [CONTACT_3621]>   
 
 
 
 
 
  
 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 Page 81 of 92  
SPONSOR SIGNATURE:  
 
I agree with the content of this protocol and the confidential nature of the documentation 
made as part of this study. I also acknowledge that the Investigator  has the right to 
discontinue the study at any time.  I have read the protocol and understand it a nd will 
ensure that the clinical trial is conducted according to it and according to the principles of 
Good Clinical Practices, applicable laws and regulations, and the Declaration of Helsinki.  
 
 
 
   
Sponsor’s Representative   Date  
[CONTACT_826830]    
 
 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 Page 82 of 92 APPENDIX A: STUDY CONTACTS  
PRINCIPAL INVESTIGATOR : 
<insert name [CONTACT_826823]>  
 
Tel:  
Fax:  
Mob:   
E-mail:   
 
INVESTIGATIONAL SITE:  
 
Tel:  
Fax:  
 
24-HOUR MEDICAL CONTACT:  
[CONTACT_826817], MBChB, HonsBSc , MedSc  
Level 9, [ADDRESS_1147092], Chatswood,  
NSW 2067, Australia  
Tel: + 61-(0)2-6653 -5013  
Fax: + 61-(0)2-6653 -5013  
Mob:  + 61-(0)434 -651-787 
E-mail:  [EMAIL_15730]  
 
SPONSOR REPRESENTATIVE:  
[CONTACT_826831] 24, [ADDRESS_1147093] , Sydney  
NSW 2000, Australia  
Tel: + 61-(0)2-9472 -4101  
Fax:  
Mob:   
E-mail:  James.Garner@ kaziatherapeutics .com  
 
BIOANALYTICAL ANALYSIS:  
TetraQ  
TetraQ – Research Infrastructure Centre  
The University of Queensland , Level 7, Block 6  
Royal Brisbane & Women's Hospi[INVESTIGATOR_826766] 4029  
Australia  
Tel: + 61-(0)7-3365 5115  
Email : [EMAIL_15731]  
 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 Page 83 of 92 LABORATORY ANALYSIS:  
Genostics Pty Ltd  
 
Tel: [PHONE_17239]  
Fax: [PHONE_17240]  
 
 
PHARMACOKINETIC ANALYSIS:  
TetraQ  
TetraQ – Research Infrastructure Centre  
The University of Queensland, Level 7, Block 6  
Royal Brisbane & Women's Hospi[INVESTIGATOR_826766] 4029  
Australia  
Tel: + 61-(0)7-3365 5115  
Email : [EMAIL_15731]  
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 Page 84 of 92 APPENDIX B: PROCEDURES FOR THE PLACEMENT OF 
THE INTRAPERITONEAL PORT/ CATHETER AND 
ADMINISTRATION OF INTRAPERITONEAL  THERAPY  
This appendix is included as a guideline to aid investigators and does not have to be 
followed explicitly. Each site should rather follow their own standard operating 
procedures for the placement of ports or catheters for intraperit oneal chemotherapy and 
intraperitoneal chemotherapy administration.  
The following device specifications have been adapted from recommendations of the 
Gynaecological Oncology Group recommendations for intraperitoneal chemotherapy: 
“Silicone catheters are pr eferred. Controversy exists between the use of venous 
9.6 silicone catheters or silicone intraperitoneal p orts with fenestrations. Bardport silicone 
peritoneal catheter 14.3 Fr (Reorder number 0603006) that is without a cuff, is the 
preferred intraperitone al catheter. This has been FDA approved for use in intraperitoneal 
therapy. The 9.6 Fr single lumen intravenous  access device, if made with silicone is 
preferred by [CONTACT_504425]. Brand names are different for different institutions due to 
contracting, and  these specifications are intended to be helpful but not limiting. 
Equivalent or similar devices are acceptable if made from silicone, large enough not to 
kink, and without a Dacron cuff. Examples of these include: Bardport MRI Implanted 
Port reorder numbe r [ADDRESS_1147094] Salt Lake City Utah [ZIP_CODE] 1 -800 545 -0890.  
Procedure at the time of a planned laparotomy:  
1. At the completion of the laparotomy just prior to closing the incision, make a 
[ADDRESS_1147095] an area several centimetres below and lateral to the umbilicus  as the 
peritoneal entrance site of the catheter. Prepare a subcutaneous tunnel from the 
portal pocket to the site in the peritoneal cavity . You want the catheter to enter the 
abdomen ; draw the catheter through the subcutaneous tissue into the abdomen 
using a tunnelling device.  
4. Attach the catheter to the portal as per manufacturer’s instructions, and suture the 
portal in place with permanent suture (i.e., 2 -0 prolene) to the fascia overlying the 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: [ADDRESS_1147096] to go through the wound to access the port; 
the port should lie superior to the port incision site.  
5. After flushing the sy stem with heparin , [ADDRESS_1147097] a Huber needle trans -dermally into the portal if the 
catheter is going to be irrigated in the immediate postoperative period. Wait a 
minimum of 24 hours prior to treating patient afte r intraperitoneal  port placement, 
and wait for return of gastrointestinal function (regular diet tolerated and normal 
bowel movement) after major laparotomy.  
Surgical implantation with mini lap. ( Video  available at SGO.org and GOG.org) :  
1. Select a site sev eral centimetres below and lateral to the umbilicus and make an 
incision through skin, subcutaneous tissue and fascia. Separate rectus muscle and 
enter peritoneum. Knowledge of the previous surgical resections and current 
anatomy will assist in choosing lo cation.  
2. Pull the catheter from subcutaneous tissue into the peritoneal cavity through the 
full thickness of the abdominal wall (fascia, muscle, peritoneum) from an adjacent 
location (not through the incision) while under direct visuali sation to prevent 
injury to bowel. This can be accomplished with a tonsil clamp or tunnelling 
device.  
3. The catheter must be left in the abdominal cavity at least [ADDRESS_1147098] 10  cm into the peritoneal cavity.  
Surgical i mplantation using laparoscopy :  
1. Laparoscopic placement of an intraperitoneal  catheter is usually feasible from a 
left upper quadrant approach. Knowledge of the previous procedures performed 
(i.e. bowel resections and re -anastomosis sites) and location of the tumour will 
inform the surgeon as to the best approach and what locations  to avoid.  
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: [ADDRESS_1147099] wall for 
appropriate port placement and catheter attachment.  
Administration of intraperitoneal t herapy:  
Treatment may be administered on an outpatient basis if deemed appropriate by [CONTACT_3786]. To allow for PK sampling, the infusion on Day [ADDRESS_1147100] operating procedures for intraperitoneal 
chemotherapy. Cantrixil is a CYP450 inhibitor; this must be kept in mind when selecting 
concomitant medications.  
Whilst the pre -medications are being admin istered, the pharmacy can prepare the 100  mL 
Cantrixil infusion and the extra 1 L saline infusion and warm the solutions according to 
institutional practice, for example using a warm water bath or blood warmer.  
For accession, the patient should be placed supi[INVESTIGATOR_826767] -Fowler’s position on a 
stretcher, adjustable bed or Gurney. Emla 2.5% cream may be applied to the port site and 
covered with occlusive dressing one hour before accessing the port. The reservoir should 
be accessed under sterile technique, gen erally using a right -angle, non -coring, [ADDRESS_1147101] wall. The port should flush easily 
without pain or oedema at the si te. Difficult or uncertain accessions can be verified by 
[CONTACT_826818] -posterior and lateral radiographs. The needle can then be secured using a 
temporary adhesive dressing. The head of the bed should be raised no higher than 
30 degrees to prevent dislodgement of the needle during infusion. A flat position during 
infusion may cause increased pressure on the diaphragm causing respi[INVESTIGATOR_826768]:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 Page 87 of 92 compromise/GI discomfort in patients receiving intraperitoneal infusions. The [ADDRESS_1147102]  under gravity. Infusion pumps are not 
recommended because they can cause needle dislocation ( Hoskins, 2006 ). Then, to 
facilitate distribution, up to 1 L of warmed nor mal saline is infused to patient tolerance.  
The position of the needle in the reservoir should be carefully determined and recorded at 
15-minute intervals. Ambulation is restricted as much as possible during infusion to avoid 
dislodgment of the needle. Pa tients should be encouraged to use the toilet before the 
procedure begins. If the bedpan is required, then the nurse or Investigator should check 
the proper needle position is maintained ( GOG ). 
The infusion nurse or physician should be aware of and check for the following 
complications which may arise during administration: nausea, vomiting, diarrhoea, 
gastro -oesophageal reflux, pain in the abdomen, chest or port site, excess abdominal 
distention, tenderness, fever, chills, dyspnoea, changes in mental status, tremors, and 
weakness. Most patients will experience some degree of abdominal bloating and 
discomfort during the infusion. The nurse or physician is responsible for  determining 
when that discomfort is appropriate to the process and when it signifies that there may be 
a problem. In the former case, the physician or nurse should be able to provide 
reassurance that these sensations are to be expected and will resolve on  conclusion of the 
infusion. In the latter, the physician or nurse should be able to quickly and easily notify 
the Principal Investigator [INVESTIGATOR_826769].  
After the infusion is complete, the infusion nurse or physician should reposition the 
patient every 15 minutes for 1 hour in the sequence listed below:  
• Head up (30°) , 
• Slight Trendelenburg , 
• Right lateral , 
• Left lateral . 
(GOG; Hoskins, 2006) . If possible, the bed can also be alternated between the 
Trendelenburg and reverse Trendelenburg positions to facilitate distribution of the 
infusion.  
After removing the Huber needle from the intraperitoneal port site, a pressure dressing 
should be place d over the port site to prevent reflux of the infusion from the port. Patients 
can remove the pressure dressing 12 to 24 hours after intraperitoneal infusion  
References:  
Hoskins, 2006  
Hoskins, P. Intraperitoneal therapy for British Columbia. BC Cancer Agen cy 
Gynecological Tumour Group (2006)  
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 Page 88 of 92 GOG  
GOG web -site: GOG Foundation, www.gog.org  
SGO  
SGO web -site: Society for Gynecologic Oncology, www.sgo.org  
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 Page 89 of 92 APPENDIX C: EVALUATION OF RESPONSE AND 
PROGRESSION USING GYNECOLOGICAL CANCER 
INTERGROUP (GCIG) RESPONSE CRITERIA  
The Gynecological Cancer Intergroup (GCIG) has published a detailed guidance on the 
criteria that could be used in clinical trial protocols to define progression and response in 
recurrent disease using RECIST 1.1 to gether with the serum marker CA -125 (Rustin et 
al., 2011). The definitions have been validated and the key summary tables have been 
reproduced below for guidance.  
Definition of a Response  
A CA -[ADDRESS_1147103] a 50% reduction in CA -[ADDRESS_1147104] reduced by 50% is the date of the CA-[ADDRESS_1147105] apply:  
1. Intervening samples and the [ADDRESS_1147106] be less than or 
equal to the previous sample (within an assay variability of 10%).  
2. The same validated assay must be used for each patient  
3. Patients are not evaluable by [CONTACT_28474] -125 if there has been a medical and/or surgical 
interference with their peritoneum during the previous 28 days. For this study, this 
means that patients are only evaluable for response based on CA -125 levels during 
the Follow -up period.  
CA-125 may be used to evaluate patients without initial measurable disease; 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: [ADDRESS_1147107] measurable disease by [CONTACT_119580], the date of response will be the 
date of the earlier of the 2 events.  
 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: [ADDRESS_1147108] Overall Response in Patients without  Initial Measura ble Disease 
and who are Evaluable  as proposed by [CONTACT_826819]-125 Non-Target 
Lesions*  New Lesions  Overall 
Serological 
Response  Best Response 
for this Category 
Also Requires  
Response and 
Normalised  CR No CR Confirmed and 
maintained for 28 
days  Response  Non-PD No PR 
Normalised but no 
Response  Non-CR/Non -PD No SD 
Non-PR/Non -PD Non-PD No SD 
PD Any Yes or No  PD 
Any PD# Yes or No  PD 
Any Any Yes PD 
*Non -target lesions include ascites and peritoneal thickening, which are not measurable by [CONTACT_393] 1.1  
#Unequivocal progression in non -target lesions may be accepted as disease progression.  
CR, Complete response; PD, progressive disease; PR, partial  response; SD, stable disease  
Table [ADDRESS_1147109] Overall Response in Patients with Measurable Disease and who are Evaluable 
by [CONTACT_28474] -125 as proposed by [CONTACT_826820]*  Non-Target# New Lesion  CA-[ADDRESS_1147110] 
Response  
CR CR No Normal  CR 
CR Non-CR Non -PD No Not PD  PR 
CR CR No PR but not normal  PR 
CR NE No PR PR 
PR Non-PD or NAE  No Not PD  PR 
NAE Non-PD No PR PR 
PD or new >28 days from CA -125 PR^  PR PR 
SD**  Non-PD No PR PR 
SD**  Non-PD or NAE  No Not PR and Not PD  SD 
PD or new ≤ 28 days from CA -125 PR^  PR PD 
PD Any Yes or No  Any PD 
Any PD Yes or No  Any PD 
Any Any Yes Any PD 
Any Any Yes or No  PD PD 
*Target lesions include up to 5 measurable lesions (2 per organ) as defined by [CONTACT_393]1.1  
#Non-target lesions include ascites and peritoneal thickening, which are not measurable by [CONTACT_393] 1.1  
^Patients who have a CA -[ADDRESS_1147111] 1.1 P D is within 28 days of CA -125 response.  
**This protocol specifies that the minimum time between 2 measurements for classification of stable disease is 6 weeks.  
CR, Complete response; PD, progressive disease; PR, partial  response; SD, stable disease ; NAE, not all evaluated; NE, 
Not evaluated.  
 
 CONFIDENTIAL  
 
Sponsor:  Kazia Therapeutics Limited  
Version 4.0 
Date 30 April 2018  Clinical Study Protocol  
Protocol Number: NVGN -002-101 
IND Number: 123275  
 
 
 Page 92 of 92 Definition of Progression  
According to the GCIG progression criteria, patient s are not evaluable by [CONTACT_28474] -125 if there 
has been a medical/or surgical interference with their peritoneum during the previous [ADDRESS_1147112]; although during Follow -up a patient 
may be declared to have PD on the basis of either the objective RECIST 1.[ADDRESS_1147113] Measurable/  Non-
measurable   CA-125 
A = Patients with elevated CA-
[ADDRESS_1147114] 1 week apart.  Compared to baseline (or 
lowest sum while on study if 
less then baseline), a 20% 
increase in sum of diameters 
(RECIST 1.1 definition)  
OR 
Any new lesions (measurable 
or non -measurable)  
OR 
Unequivocal increase in non -
target disease  
Date of PD: date of 
documentation of increase or 
new lesions  AND/  
OR CA-125 ≥ 2x ULRR 
documented on 2 occasions*  
Date of PD: first date of the 
CA-125 elevation to ≥ 2x 
ULRR  
B = Patients with elevated CA -
[ADDRESS_1147115] 1 week apart  As for A  CA-125 ≥ 2x nadir value on 2 
occasions*  
Date of PD: first date of the 
CA-125 elevation to ≥ 2x nadir 
value  
C = Patients with CA -[ADDRESS_1147116] 1 week apart.  As for A  As for A  
*Repeat CA -[ADDRESS_1147117] elevated CA -125 level.  
ULRR, upper limit of response range  
 